Palladium catalyst compositions and methods for sequencing while synthesizing

By using water-soluble macrocycles and additives in the cleavage solution, the stability and activity of palladium catalysts in sequencing by synthesis are enhanced, addressing thermal and oxidative instability issues and improving sequencing accuracy.

CN119095982AInactive Publication Date: 2024-12-06ILLUMINA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031854.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-12-22
Filing Date
2023-12-20
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing palladium catalysts used in sequencing by synthesis (SBS) suffer from thermal and oxidative instability, leading to reduced cleavage activity and the formation of Pd clusters, which affect sequencing accuracy and instrument stability.

Method used

Incorporating water-soluble macrocycles and additional additives such as oxygen scavengers and phosphine reducing agents into the aqueous cleavage solution to enhance the thermal and oxidative stability of the palladium catalyst, preventing Pd cluster formation and maintaining cleavage efficiency.

Benefits of technology

Improves the stability and cleavage activity of palladium catalysts, reducing phasing errors and enhancing the reliability of sequencing by synthesis processes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095982A_ABST
    Figure CN119095982A_ABST
Patent Text Reader

Abstract

The invention relates to palladium catalyst compositions and uses in sequencing while synthesizing. In particular, the Pd catalyst composition comprises one or more macrocycles (e.g., cyclodextrins or analogs thereof) as an additive for improving the thermal or oxidative stability of the active Pd (0) species.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure generally relates to polynucleotide sequencing methods, compositions, and kits for sequencing. Background Art

[0002] Progress in molecular research has always been driven, in part, by improvements in techniques used to characterize molecules or their biological reactions. In particular, the study of nucleic acids DNA and RNA has benefited from the development of techniques for sequence analysis and the study of hybridization events.

[0003] An example of the technology of improved nucleic acid research is to develop an assembly array of immobilized nucleic acids. These arrays are usually composed of a high-density matrix of polynucleotides fixed to a solid support material. See, for example, Fodor et al., Trends Biotech. 12: 19-26, 1994, which describes a method for assembling nucleic acids using a chemically sensitized glass surface, which is protected by a mask but exposed in a limited area to allow the connection of appropriately modified nucleotide phosphoramidites. Assembly arrays can also be manufactured by "spotting" known polynucleotides to predetermined positions on a solid support (e.g., Stimpson et al., Proc. Natl. Acad. Sci. 92: 6379-6383, 1995).

[0004] One method of determining the nucleotide sequence of nucleic acids bound to an array is called "sequencing by synthesis" or "SBS". Ideally, this technique for determining the nucleotide sequence of DNA requires the controlled incorporation (i.e., one at a time) of the correct complementary nucleotide opposite to the nucleic acid being sequenced. This enables accurate sequencing by adding nucleotides in multiple cycles, since only one nucleotide residue is sequenced at a time, thereby preventing uncontrolled incorporation of nucleotide sequences. The incorporated nucleotides are read using an appropriate label attached to the incorporated nucleotides, after which the label portion is removed and the next round of sequencing is performed.

[0005] In order to ensure that only a single nucleotide is incorporated, a structural modification ("protecting group" or "capping group") is included in each labeled nucleotide, which is added to the growing chain to ensure that only one nucleotide is incorporated. After the nucleotide with the protecting group is added, the protecting group is removed under reaction conditions that do not interfere with the integrity of the DNA being sequenced. The sequencing cycle can then continue with the incorporation of the next protected labeled nucleotide. In order to be used for DNA sequencing, nucleotides (usually nucleotide triphosphates) generally require a 3'-hydroxyl capping group so that once a base is added to the nucleotide, the polymerase used to incorporate it into the polynucleotide chain is prevented from continuing to replicate.

[0006] Each step of the sequencing cycle uses a different composition. For example, an incorporation composition comprising a polymerase and one or more different types of nucleotides is used during the incorporation step. The scanning composition can include an antioxidant in particular, which protects the polynucleotide from light-induced damage during the detection step, for example, when the nucleotide includes a fluorophore label for detection. During the deblocking step, a deblocking composition is used, which includes a reagent for cleaving the end-blocking portion (for example, 3' hydroxyl end-blocking group) from the incorporated nucleotide. Cleavage reagents, such as palladium (Pd) catalysts prepared from palladium complexes in the presence of water-soluble phosphine ligands, have been reported in deblocking compositions, for example, U.S. Publication Nos. 2020 / 0216891 and 2021 / 0403500, each of which is incorporated by reference in its entirety. Pd has the ability to adhere to DNA primarily in its inactivated Pd (II) form, which may interfere with the binding between DNA and polymerase, thereby resulting in increased phasing. After the deblocking step, a post-cleavage washing composition comprising a Pd scavenger compound can be used. For example, PCT Publication No. WO 2020 / 126593 discloses that Pd scavengers (such as 3,3'-dithiodipropionic acid (DDPA) and lipoic acid (LA)) can be included in the scanning composition and / or the post-cleavage washing composition. In addition, active Pd(0) can decompose under oxygen or thermal stress, thereby reducing cleavage activity and increasing phasing during sequencing. In addition, the thermal decomposition of Pd(0) may form Pd clusters and eventually form Pd black aggregates on the substrate, which may have a negative impact on instrument stability. However, there is a continuous demand for developing Pd cleavage compositions with improved thermal and / or oxidative stability for sequencing applications. Summary of the invention

[0007] One aspect of the present disclosure relates to a method for determining the sequence of a plurality of target polynucleotides, the method comprising:

[0008] (a) contacting a solid support with a spiked mixture comprising a DNA polymerase and one or more types of nucleotides of four different types of nucleotides and a sequencing primer that is complementary to and hybridizes to at least a portion of the target polynucleotide, wherein the solid support comprises a plurality of different target polynucleotides immobilized thereon;

[0009] (b) incorporating one type of nucleotide into the sequencing primer to generate an extended copy polynucleotide, wherein each of the four types of nucleotides comprises a 3'

[0010] Capping group;

[0011] (c) imaging the extended copy polynucleotide and performing one or more fluorescence measurements; and

[0012] (d) removing the 3' blocking group of the incorporated nucleotide in an aqueous cleavage solution comprising an active palladium catalyst;

[0013] wherein the aqueous cleavage solution comprises one or more additives for improving the thermal or oxidative stability of the active palladium catalyst, and wherein the one or more additives comprise one or more water-soluble macrocycles.

[0014] Another aspect of the present disclosure relates to a method for improving the stability of a composition comprising an active palladium catalyst, the method comprising: mixing an aqueous composition comprising a Pd(0) catalyst with one or more additives for improving the thermal or oxidative stability of the active palladium catalyst, and wherein the one or more additives comprise one or more water-soluble macrocycles. In some additional embodiments, the additive in the aqueous cleavage solution further comprises one or more oxygen scavengers and / or phosphine reducing agents.

[0015] Another aspect of the present disclosure relates to a kit for use with a sequencing device, the kit comprising: an aqueous cleavage mixture comprising an active Pd(0) catalyst; and one or more additives for improving the thermal or oxidative stability of the active Pd(0) catalyst, and wherein the one or more additives comprise one or more water-soluble macrocycles. In some additional embodiments, the additives in the aqueous cleavage solution further comprise one or more oxygen scavengers and / or phosphine reducing agents.

[0016] Additional aspects of the present disclosure relate to a cartridge for use with a sequencing apparatus, the cartridge comprising a plurality of chambers, wherein one or more of the plurality of chambers are for use with a kit comprising an aqueous lysis mixture as described herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1A is a line graph showing the percentage of cleavage of the 3' capping group as a function of time for a standard Pd cleavage mixture (UCM) before and after 5 hours of oxygen stress compared to a control UCM.

[0018] Figure 1B is dynamic light scattering (DLS) data showing the formation of Pd clusters in a standard Pd cleavage mixture (UCM) after 7 days of thermal stress at 55°C compared to a fresh control.

[0019] Figure 2 is a line graph of the percent Pd(0) remaining after 5 hours of oxygen stress in a plate reader assay using a standard lysis mixture (UCM) as a control compared to two lysis mixtures with water-soluble cyclodextrin analogs according to certain embodiments of the present disclosure.

[0020] Figure 3Ais a bar graph showing the percentage of cleavage of the 3' capping group over time at 1 minute and 60 minutes using a standard cleavage mixture (UCM) exposed to oxygen for 5 hours as a control, compared to three oxygen stress cleavage mixtures with water-soluble cyclodextrin analogs according to certain embodiments of the present disclosure.

[0021] Figure 3B is dynamic light scattering (DLS) data showing that including cyclodextrin analogs in the standard lysis mixture (UCM) to prevent the formation of Pd clusters after 7 days of thermal stress at 55°C improved thermal stability compared to a standard lysis mixture (UCM) control without added cyclodextrin analogs.

[0022] Figure 4 is a bar graph of the percent cleavage of the 3' capping group over time at 1 minute and 60 minutes using a standard cleavage mixture (UCM) exposed to oxygen for 24 hours as a control, compared to oxygen stressed UCMs with various oxygen scavengers or phosphine reductants according to embodiments of the present disclosure. DETAILED DESCRIPTION

[0023] Some aspects of the present disclosure relate to methods for nucleic acid sequencing. In particular, sequencing methods described herein include using an aqueous cleavage mixture containing a Pd(0) catalyst to cleave the 3' hydroxyl-terminated groups of the nucleotides incorporated before the next incorporation cycle, wherein the aqueous cleavage mixture comprises one or more macrocycles (e.g., cyclodextrin, calixarene or cucurbituril, or its optionally substituted analogs, salts or hydrates) as additives for improving the thermal and / or oxidative stability of the active palladium catalyst. In addition, the aqueous cleavage mixture may include additional additives, such as one or more oxygen scavengers and / or one or more phosphine reducing agents. Active Pd(0) substances can be decomposed under two independent mechanisms. Thermal stress leads to thermal degradation of Pd(0) and the formation of Pd clusters, and finally Pd black precipitation. In addition, due to the oxidative degradation of the Pd(0) substance, oxygen stress can also significantly reduce the cleavage activity. In some embodiments, one or more additives described herein prevent or reduce the thermal degradation of the active Pd catalyst, and also prevent or reduce the formation of Pd clusters, and thus improve the thermal stability of the cleavage mixture. In some additional embodiments, the additive also prevents or reduces oxidation of the Pd cleavage mixture, and thus improves the oxidative stability of the Pd cleavage mixture.Some aspects of the present disclosure are generally directed to methods of removing 3' capping groups.

[0024] definition

[0025] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art. The use of the term "including" and other forms such as "include", "includes", and "included" is not restrictive. The use of the term "having" and other forms such as "have", "has", and "had" is not restrictive. As used in this specification, whether in a transitional phrase or in the body of the claim, the terms "including" and "including" will be interpreted as having an open meaning. That is, the above terms should be interpreted synonymously with the phrases "at least having" or "at least including". For example, when used in the context of a process, the term "including" means that the process includes at least the steps listed, but may also include additional steps. When used in the context of a compound, composition, or device, the term "including" means that the compound, composition, or device includes at least the listed features or components, but may also include additional features or components.

[0026] Where a range of values ​​is provided, it is understood that the upper and lower limit of that range and every intervening value between the upper and lower limits is encompassed within the embodiments.

[0027] As used herein, common organic abbreviations are defined as follows:

[0028] ℃ Temperature in degrees Celsius

[0029] dATP deoxyadenosine triphosphate

[0030] dCTP deoxycytidine triphosphate

[0031] dGTP deoxyguanosine triphosphate

[0032] dTTP deoxythymidine triphosphate

[0033] ddNTP dideoxynucleotide triphosphate

[0034] ffN Fully functionalized nucleotides

[0035] ffA Fully functionalized "A" nucleotide

[0036] ffC Fully functionalized "C" nucleotides

[0037] ffT Fully functionalized "T" nucleotides

[0038] ffG Fully functionalized "G" nucleotides

[0039] IMX Incorporation mix or Incorporation mixture

[0040] Pd Palladium

[0041] RT Room temperature

[0042] SBS Sequencing by Synthesis

[0043] As used herein, the term "array" refers to a group of different probe molecules connected to one or more substrates so that these different probe molecules can be distinguished from each other according to relative positions. The array may include different probe molecules at different addressable positions located on the substrate. Alternatively or in addition thereto, the array may include a separate substrate with different probe molecules, wherein different probe molecules can be identified according to the position of the substrate on the surface to which the substrate is connected or according to the position of the substrate in the liquid. The exemplary array wherein the separate substrate is located on the surface includes but is not limited to those comprising beads in the hole, such as, for example, U.S. Patent No. 6,355,431B1, US2002 / 0102578 and PCT published in WO 00 / 63437. For example, in U.S. Patent No. 6,524,793, it is described that the exemplary form of beads in the liquid array can be used for example using a microfluidic device, such as a fluorescence activated cell sorter (FACS) is distinguished in the present invention. Additional examples of arrays that can be used in the present invention include, but are not limited to, U.S. Patents 5,429,807; 5,436,327; 5,561,071; 5,583,211; 5,658,734; 5,837,858; 5,874,219; 5,919,523; 6,136,269; 6,287,768; 6,287,776; 6,288,220; 6,297,006; 6,291,193; 6,346,413; 6,416,949; 6,482,591; 6,514,751 and 6,610,482; and WO 93 / 17126; WO 95 / 11995; WO 95 / 35505; EP 742 287; and EP Those described in 799 897.

[0044] As used herein, the term "covalently attached" or "covalently bonded" refers to the formation of a chemical bond characterized by the sharing of electron pairs between atoms. For example, a covalently attached polymer coating refers to a polymer coating that forms a chemical bond with a functionalized surface of a substrate, as opposed to adhering to the surface via other means (e.g., adhesion or electrostatic interaction). It should be understood that a polymer covalently attached to a surface may also be bonded via means other than covalent attachment.

[0045] As used herein, "inactivating" or "inactivating" a palladium catalyst includes, but is not limited to, the following mechanisms using a palladium scavenger: (1) the palladium scavenger can act as a competitive substrate that consumes any residual active Pd(0) attached to the nucleic acid; (2) the palladium scavenger can act as an oxidizing agent that converts the active Pd(0) to the inactive Pd(II) form; and (3) the palladium scavenger can act as a competitive ligand that removes Pd (e.g., Pd(0) or Pd(II)) attached to the nucleic acid.

[0046] As used herein, any "R" group refers to a substituent that may be attached to the designated atom. The R group may be substituted or unsubstituted.

[0047] It is understood that certain group naming conventions may include either a monoradical or a diradical, depending on the context. For example, when a substituent requires two points of attachment to the rest of the molecule, it is understood that the substituent is a diradical. For example, a substituent identified as an alkyl group requiring two points of attachment includes a diradical, such as -CH2-, -CH2CH2-, -CH2CH(CH3)CH2-, etc. Other group naming conventions clearly indicate that the group is a diradical, such as "alkylene" or "alkenylene".

[0048] As used herein, the term "halogen" or "halo" means any of the radioactive stable atoms of column 7 of the periodic table, for example, fluorine, chlorine, bromine or iodine, with fluorine and chlorine being preferred.

[0049] As used herein, "C" wherein "a" and "b" are integers a To C b " or "C a -C b " or "C a-b" refers to the number of carbon atoms in an alkyl, alkenyl, or alkynyl group, or the number of ring atoms in a cycloalkyl or aryl group. That is, the rings of alkyl, alkenyl, alkynyl, cycloalkyl, and aryl groups can contain from "a" to "b" (inclusive) carbon atoms. For example, a "C1 to C4 alkyl" group refers to all alkyl groups having from 1 to 4 carbons, i.e., CH3-, CH3CH2-, CH3CH2CH2-, (CH3)2CH-, CH3CH2CH2 CH2-, CH3CH2CH(CH3)- and (CH3)3C-; C3 to C4 cycloalkyl groups refer to all cycloalkyl groups having 3 to 4 carbon atoms, i.e., cyclopropyl and cyclobutyl. Similarly, a "4 to 6 membered heterocyclyl" group refers to all heterocyclyl groups having 4 to 6 total ring atoms, such as azetidine, oxetane, oxazoline, pyrrolidine, piperidine, piperazine, morpholine, etc. If there is no alkyl, alkenyl, alkynyl, cycloalkyl or aryl group, the alkyl group may be used. If "a" and "b" are specified, the broadest range described in these definitions will be assumed. As used herein, the term "C1-C6" includes C1, C2, C3, C4, C5, and C6, as well as ranges defined by either of these two numbers. For example, C1-C6 alkyl includes C1 alkyl, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl, C2-C6 alkyl, C1-C3 alkyl, etc. Similarly, C2-C6 alkenyl includes C2 alkenyl, C3 alkenyl, C4 alkenyl, C5 alkenyl, and C6 alkenyl. C3-C8 cycloalkyl groups include hydrocarbon rings containing 3, 4, 5, 6, 7 and 8 carbon atoms or ranges defined by any two numbers, such as C3-C7 cycloalkyl groups or C5-C6 cycloalkyl groups.

[0050] As used herein, "alkyl" refers to a straight or branched hydrocarbon chain that is fully saturated (i.e., does not contain double bonds and triple bonds). An alkyl group may have 1 to 20 carbon atoms (whenever it appears in this article, a numerical range such as "1 to 20" refers to each integer in the given range; for example, "1 to 20 carbon atoms" means that the alkyl group may be composed of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, but this definition also covers the term "alkyl" in which no numerical range is specified). The alkyl group may also be a medium-sized alkyl group having 1 to 9 carbon atoms. The alkyl group may also be a low-sized alkyl group having 1 to 6 carbon atoms. The alkyl group may be designated as "C 1- C4 alkyl" or similar designations. By way of example only, "C 1-"C6 alkyl" means that there are one to six carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, and the like.

[0051] As used herein, "alkoxy" refers to a radical of the formula --OR (wherein R is an alkyl radical as defined above), such as "C 1- "C9 alkoxy" includes, but is not limited to, methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, isobutoxy, sec-butoxy and tert-butoxy, etc.

[0052] As used herein, "alkenyl" refers to a straight or branched hydrocarbon chain containing one or more double bonds. An alkenyl group may have from 2 to 20 carbon atoms, but this definition also encompasses the term "alkenyl" where no numerical range is specified. An alkenyl group may also be a medium-sized alkenyl group having from 2 to 9 carbon atoms. An alkenyl group may also be a lower alkenyl group having from 2 to 6 carbon atoms. An alkenyl group may be designated as "C 2- C6 alkenyl" or similar designations. By way of example only, "C 2- "C6 alkenyl" means that there are two to six carbon atoms in the alkenyl chain, that is, the alkenyl chain is selected from the group consisting of ethenyl, propen-1-yl, propen-2-yl, propen-3-yl, buten-1-yl, buten-2-yl, buten-3-yl, buten-4-yl, 1-methyl-propen-1-yl, 2-methyl-propen-1-yl, 1-ethyl-ethen-1-yl, 2-methyl-propen-3-yl, buta-1,3-dienyl, buta-1,2-dienyl and buta-1,2-dien-4-yl. Typical alkenyl groups include, but are by no means limited to, ethenyl, propenyl, butenyl, pentenyl and hexenyl, etc.

[0053] The term "aromatic" refers to a ring or ring system having a conjugated π electron system, and includes both carbocyclic aromatic groups (e.g., phenyl) and heterocyclic aromatic groups (e.g., pyridine). The term includes monocyclic groups or fused-ring polycyclic (i.e., rings that share adjacent pairs of atoms) groups, provided that the entire ring system is aromatic.

[0054] As used herein, "aryl" refers to an aromatic ring or ring system (i.e., two or more fused rings that share two adjacent carbon atoms) that contains only carbon in the ring backbone. When aryl is a ring system, each ring in the ring system is aromatic. Aryl groups can have 6 to 18 carbon atoms, but this definition also covers the term "aryl" that appears without a specified numerical range. In some embodiments, aryl groups have 6 to 10 carbon atoms. Aryl groups can be designated as "C6-C 10 Aryl", "C6 or C10 Examples of aryl groups include, but are not limited to, phenyl, naphthyl, azulenyl, and anthracenyl.

[0055] "Aralkyl" or "arylalkyl" is an aryl group attached as a substituent through an alkylene group, such as "C 7-14 "Aralkyl" and the like, including but not limited to benzyl, 2-phenylethyl, 3-phenylpropyl and naphthylalkyl. In some cases, the alkylene group is a lower alkylene group (i.e., C 1- C6 alkylene group).

[0056] As used herein, "aryloxy" refers to RO-, where R is aryl as defined above, such as but not limited to phenyl.

[0057] As used herein, "heteroaryl" refers to an aromatic ring or ring system (i.e., two or more condensed rings sharing two adjacent atoms) containing one or more heteroatoms (i.e., elements other than carbon, including but not limited to nitrogen, oxygen and sulfur) in the ring skeleton. When heteroaryl is a ring system, each ring in the ring system is aromatic. The heteroaryl group can have 5 to 18 ring members (i.e., the number of atoms (including carbon atoms and heteroatoms) constituting the ring skeleton), but the present definition also encompasses the term "heteroaryl" in which no numerical range is specified. In some embodiments, the heteroaryl group has 5 to 10 ring members or 5 to 7 ring members. The heteroaryl group can be named "5 to 7 yuan heteroaryl", "5 to 10 yuan heteroaryl" or similar names. Examples of heteroaryl rings include, but are not limited to, furanyl, thienyl, phthalazinyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, quinolyl, isoquinolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, indolyl, isoindolyl, and benzothiophenyl.

[0058] "Heteroaralkyl" or "heteroarylalkyl" is a heteroaryl group attached as a substituent via an alkylene group. Examples include, but are not limited to, 2-thienylmethyl, 3-thienylmethyl, furanylmethyl, thienylethyl, pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl, and imidazolylalkyl. In some cases, the alkylene group is a lower alkylene group (i.e., C 1- C6 alkylene group).

[0059] As used herein, "carbocyclyl" means a non-aromatic cyclic ring or ring system containing only carbon atoms in the ring system skeleton. When the carbocyclyl is a ring system, two or more rings can be joined together in a fused, bridged or spiro manner. The carbocyclyl can have any degree of saturation, provided that at least one ring in the ring system is not aromatic. Therefore, carbocyclyl includes cycloalkyl, cycloalkenyl and cycloalkynyl. The carbocyclyl group can have 3 to 20 carbon atoms, but this definition also covers the term "carbocyclyl" in which no numerical range is specified. The carbocyclyl group can also be a medium-sized carbocyclyl with 3 to 10 carbon atoms. The carbocyclyl group can also be a carbocyclyl with 3 to 6 carbon atoms. The carbocyclyl group can be named "C 3- C6 carbocyclyl" or similar designations. Examples of carbocyclyl rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,3-dihydro-indene, bicyclo[2.2.2]octanyl, adamantyl, and spiro[4.4]nonanyl.

[0060] As used herein, "cycloalkyl" means a fully saturated carbocyclyl ring or ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0061] As used herein, "heterocyclyl" refers to a non-aromatic cyclic ring or ring system containing at least one heteroatom in the ring backbone. The heterocyclyl group can be joined together in a fused, bridged or spiro manner. The heterocyclyl group can have any degree of saturation, provided that at least one ring in the ring system is not aromatic. The heteroatom can be present in a non-aromatic ring or an aromatic ring in the ring system. The heterocyclyl group can have 3 to 20 ring members (i.e., the number of atoms (including carbon atoms and heteroatoms) constituting the ring backbone), but this definition also covers the term "heterocyclyl" in which no numerical range is specified. The heterocyclyl group can also be a medium-sized heterocyclyl group with 3 to 10 ring members. The heterocyclyl group can also be a heterocyclyl group with 3 to 6 ring members. The heterocyclyl group can be named "3 to 6-membered heterocyclyl" or similar names. In preferred six-membered monocyclic heterocyclyls, the heteroatoms are selected from one to a maximum of three from O, N or S, and in preferred five-membered monocyclic heterocyclyls, the heteroatoms are selected from one or two heteroatoms selected from O, N or S. Examples of heterocyclyl rings include, but are not limited to, azepinyl, acridinyl, carbazolyl, cinnolinyl, dioxolanyl, imidazolinyl, imidazolidinyl, morpholinyl, oxiranyl, oxepanyl, thiepanyl, piperidinyl, piperazinyl, dioxopiperazinyl, pyrrolidinyl, pyrrolidonyl, pyrrolidinedionyl, 4-piperidonyl, pyrazolinyl, pyrazolidinyl, 1,3-dioxinyl, 1,3-dioxinyl, 1,4-dioxinyl, 1,4-dioxinyl, 1,3-oxathianyl, 1,4-oxathianyl, 1,4-oxathianyl, 2 H-1,2-oxazinyl, trioxanyl, hexahydro-1,3,5-triazinyl, 1,3-dioxolyl, 1,3-dioxolanyl, 1,3-dithienyl, 1,3-dithianyl, isoxazolinyl, isoxazolidinyl, oxazolinyl, oxazolidinyl, oxazolidinone, thiazolinyl, thiazolidinyl, 1,3-oxathiolanyl, indolinyl, isoindolinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydrothiopyranyl, tetrahydro-1,4-thiazinyl, thiomorpholinyl, dihydrobenzofuranyl, benzimidazolidinyl and tetrahydroquinoline.

[0062] As used herein, "(aryl)alkyl" refers to an aryl group as defined above attached as a substituent via an alkylene group as described above. The alkylene and aryl groups of the aralkyl group may be substituted or unsubstituted. Examples include, but are not limited to, benzyl, 2-phenylalkyl, 3-phenylalkyl, and naphthylalkyl. In some embodiments, the alkylene group is an unsubstituted straight chain containing 1, 2, 3, 4, 5, or 6 methylene units.

[0063] As used herein, "(heteroaryl)alkyl" refers to a heteroaryl group as defined above attached as a substituent via an alkylene group as defined above. The alkylene and heteroaryl groups of the heteroaralkyl group may be substituted or unsubstituted. Examples include, but are not limited to, 2-thienylalkyl, 3-thienylalkyl, furanylalkyl, thienylalkyl, pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl, and imidazolylalkyl, and their benzo-fused analogs. In some embodiments, the alkylene group is an unsubstituted straight chain containing 1, 2, 3, 4, 5, or 6 methylene units.

[0064] As used herein, "(heterocyclyl)alkyl" refers to a heterocycle or heterocyclyl group as defined above connected as a substituent via an alkylene group as defined above. The alkylene group and heterocyclyl group of the (heterocyclyl)alkyl can be substituted or unsubstituted. Examples include, but are not limited to, (tetrahydro-2H-pyran-4-yl)methyl, (piperidin-4-yl)ethyl, (piperidin-4-yl)propyl, (tetrahydro-2H-thiopyran-4-yl)methyl and (1,3-thiazin-4-yl)methyl. In some embodiments, the alkylene group is an unsubstituted straight chain containing 1, 2, 3, 4, 5 or 6 methylene units.

[0065] As used herein, "(carbocyclyl)alkyl" refers to a carbocyclyl group (as defined herein) attached as a substituent via an alkylene group. Examples include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylethyl, and cyclohexylpropyl. In some embodiments, the alkylene group is an unsubstituted straight chain containing 1, 2, 3, 4, 5, or 6 methylene units.

[0066] As used herein, "alkoxyalkyl" or "(alkoxy)alkyl" refers to an alkoxy group attached through an alkylene group, such as C2-C8alkoxyalkyl or (C1-C6alkoxy)C1-C6alkyl, for example -(CH2) 1-3 -OCH3.

[0067] As used herein, "-O-alkoxyalkyl" or "-O-(alkoxy)alkyl" refers to an alkoxy group attached via an -O-(alkylene) group, such as -O-(C1-C6alkoxy)C1-C6alkyl, e.g. -O-(CH2) 1-3 -OCH3.

[0068] As used herein, "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by a halogen (e.g., monohaloalkyl, dihaloalkyl, and trihaloalkyl). Such groups include, but are not limited to, chloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, and 1-chloro-2-fluoromethyl, 2-fluoroisobutyl. The haloalkyl group may be substituted or unsubstituted.

[0069] As used herein, "haloalkoxy" refers to an alkoxy group in which one or more hydrogen atoms are replaced by a halogen (e.g., monohaloalkoxy, dihaloalkoxy, and trihaloalkoxy). Such groups include, but are not limited to, chloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, and 1-chloro-2-fluoromethoxy, 2-fluoroisobutoxy. The haloalkoxy group may be substituted or unsubstituted.

[0070] An "amino" group refers to a -NH2 group. As used herein, the term "monosubstituted amino group" refers to an amino (-NH2) group in which one hydrogen atom is replaced by a substituent. As used herein, the term "disubstituted amino group" refers to an amino (-NH2) group in which each of the two hydrogen atoms is replaced by a substituent. As used herein, the term "optionally substituted amino" refers to a -NR A R B Group, where R A and R B and R is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl or heterocyclyl(alkyl), as defined herein.

[0071] An "O-carboxyl" group is one in which R is selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 Aryl, 5- to 10-membered heteroaryl, and 3- to 10-membered heterocyclyl "-OC(=O)R" groups are as defined herein.

[0072] A "C-carboxyl" group is one in which R is selected from the group consisting of hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 The "-C(=O)OR" group of the group consisting of aryl, 5- to 10-membered heteroaryl, and 3- to 10-membered heterocyclyl, as defined herein. Non-limiting examples include carboxyl (ie, -C(=O)OH).

[0073] A "sulfonyl" group is a group in which R is selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 The "-SO2R" group of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclyl are as defined herein.

[0074] A "sulfinyl" group refers to a "-S(=O)OH" group.

[0075] A "sulfo" group refers to a "-S(=O)2OH" or a "-SO3H" group.

[0076] A "sulfonate" group refers to a "-SO3" group.

[0077] A "sulfate" group refers to a "-SO4ˉ" group.

[0078] An "S-sulfonamido" group refers to a group in which R A and R B are each independently selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 "-SO2NR" of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclic group A R B " group, as defined herein.

[0079] An "N-sulfonamido" group is one in which R A and R B are each independently selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 "-N(R)" of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclic group A )SO2R B " group, as defined herein.

[0080] A "C-amido" group is one in which R A and R B are each independently selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 "-C(=O)NR" of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclic group A R B " group, as defined herein.

[0081] An "N-amido" group is one in which R A and R Bare each independently selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 "-N(R)" of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclic group A )C(=O)R B " group, as defined herein.

[0082] An "O-carbamyl" group refers to a "-OC(=O)N(R A R B )" group, wherein R A and R B The O-carbamyl group may be substituted or unsubstituted.

[0083] An "N-carbamyl" group refers to an "ROC(=O)N(R A )-" group, where R and R A The same definition as for N-sulfonylamino may be used. The N-carbamoyl group may be substituted or unsubstituted.

[0084] An "O-thiocarbamyl" group refers to an "-OC(=S)-N(R A R B )" group, wherein R A and R B The O-thiocarbamoyl group may be substituted or unsubstituted.

[0085] An "N-thiocarbamyl" group refers to an "ROC(=S)N(R A )-" group, where R and R A The same definition as for N-sulfonylamino group may be used. The N-thiocarbamoyl group may be substituted or unsubstituted.

[0086] The term "alkylamino" or "(alkyl)amino" refers to an amino group in which one or both hydrogen atoms are replaced by an alkyl group.

[0087] An "(alkoxy)alkyl" group refers to an alkoxy group attached through an alkylene group, such as "(C 1- C6 alkoxy)C 1- C6 alkyl" etc.

[0088] The term "hydroxyl" as used herein refers to an -OH group.

[0089] The term "cyano" as used herein refers to a "-CN" group.

[0090] The term "azido" as used herein refers to a -N3 group.

[0091] The term "succinyl" as used herein refers to a -C(=O)CH2CH2C(=O)OH group.

[0092] When a group is described as "optionally substituted," it may be unsubstituted or substituted. Likewise, when a group is described as "substituted," the substituents may be selected from one or more of the indicated substituents. As used herein, a substituted group is derived from an unsubstituted parent group in which there has been an exchange of one or more hydrogen atoms with another atom or group.Unless otherwise specified, when a group is considered to be "substituted", it means that the group is substituted by one or more substituents independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 heteroalkyl, C3-C7 carbocyclyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), C3-C7 carbocyclyl-C1-C6-alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), 3-10 membered heterocyclyl C1-C6-alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), 3-10 membered heterocyclyl-C1-C6-alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), aryl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), (aryl)C1-C6 alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), C1-C6 alkoxy), 5-10 membered heteroaryl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), (5-10 membered heteroaryl)C1-C6 alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), halo, -CN, hydroxy, C1-C6 alkoxy, (C1-C6 alkoxy)C1-C6 alkyl, -O(C1-C6 alkoxy)C1-C6 alkyl; (C1-C6 haloalkoxy)C1-C6 alkyl; -O(C1-C6 haloalkoxy) )C1-C6 alkyl; aryloxy, thiol (sulfhydryl), halo(C1-C6)alkyl (e.g., –CF3), halo(C1-C6)alkoxy (e.g., –OCF3), C1-C6 alkylthio, arylthio, amino, amino(C1-C6)alkyl, nitro, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-acylamino, N-acylamino, S-sulfonylamino, N-sulfonylamino, C-carboxy, O-carboxy, acyl, cyanate, isocyanate, thiocyanate, isothiocyanate, sulfinyl, sulfonyl, -SO3H, sulfonate, sulfate, sulfinyl, -OSO2C. 1-4 Alkyl, monophosphate, diphosphate, triphosphate and oxo (=0). Wherever a group is described as "optionally substituted", the group may be substituted with the above substituents.

[0093] As will be appreciated by those of ordinary skill in the art, the compounds described herein may exist in an ionized form, for example, -CO2 ˉ 、-SO3 ˉ or –O-SO3 ˉ If the compound contains a positively or negatively charged substituent group, e.g., -SO3 ˉ , it may also contain negatively or positively charged counterions so that the compound is neutral as a whole. In other aspects, the compound may exist in the form of a salt, wherein the counterion is provided by a conjugate acid or base.

[0094] As used herein, "nucleotides" include nitrogenous heterocyclic bases, sugars, and one or more phosphate groups. They are monomeric units of nucleic acid sequences. In RNA, the sugar is ribose, and in DNA it is deoxyribose, i.e., a sugar lacking the hydroxyl groups present in ribose. The nitrogenous heterocyclic bases may be purine or pyrimidine bases. Purine bases include adenine (A) and guanine (G) and their modified derivatives or analogs, such as 7-deazaadenine or 7-deazaguanine. Pyrimidine bases include cytosine (C), thymine (T) and uracil (U) and their modified derivatives or analogs. The C-1 atom of deoxyribose is bonded to the N-1 of pyrimidine or the N-9 of purine.

[0095] As used herein, "nucleoside" is structurally similar to a nucleotide, but lacks a phosphate moiety. An example of a nucleoside analog is a nucleoside analog in which a label is attached to a base and no phosphate group is attached to a sugar molecule. The term "nucleoside" is used herein in the conventional sense as understood by those skilled in the art. Examples include, but are not limited to, ribonucleosides comprising a ribose moiety and deoxyribonucleosides comprising a deoxyribose moiety. A modified pentose moiety is a pentose moiety in which an oxygen atom has been replaced by a carbon and / or a carbon has been replaced by a sulfur or oxygen atom. A "nucleoside" is a monomer that may have a substituted base and / or sugar moiety. In addition, nucleosides may be incorporated into larger DNA and / or RNA polymers and oligomers.

[0096] The term "purine base" is used herein with the common meaning understood by those skilled in the art, and includes its tautomers. Similarly, the term "pyrimidine base" is used herein with the common meaning understood by those skilled in the art, and includes its tautomers. The non-limiting list of optionally substituted purine bases includes purine, adenine, guanine, deazapurine, 7-deazaadenine, 7-deazaguanine, hypoxanthine, xanthine, alloxanthine, 7-alkylguanine (e.g., 7-methylguanine), theobromine, caffeine, uric acid, and isoguanine. The example of pyrimidine bases includes, but is not limited to, cytosine, thymine, uracil, 5,6-dihydrouracil, and 5-alkylcytosine (e.g., 5-methylcytosine).

[0097] As used herein, when an oligonucleotide or polynucleotide is described as "comprising" or "incorporating" a nucleoside or nucleotide as described herein, this means that a nucleoside or nucleotide as described herein forms a covalent bond with an oligonucleotide or polynucleotide. Similarly, when a nucleoside or nucleotide is described as a part of an oligonucleotide or polynucleotide, such as "incorporating" an oligonucleotide or polynucleotide, this means that a nucleoside or nucleotide as described herein forms a covalent bond with an oligonucleotide or polynucleotide. In some such embodiments, a covalent bond is formed between the 5' phosphate group of the nucleotide of the 3' hydroxyl of an oligonucleotide or polynucleotide and the 5' carbon atom of the phosphodiester bond described herein as a 3' carbon atom of an oligonucleotide or polynucleotide and a nucleotide.

[0098] As used herein, the term "cleavable linker" is not intended to imply that the entire linker needs to be removed. The cleavage site can be located at a position on the linker that ensures that a portion of the linker remains attached to the detectable label and / or nucleoside or nucleotide moiety after cleavage.

[0099] As used herein, "derivative" or "analog" means a synthetic nucleotide or nucleoside derivative with a modified base moiety and / or a modified sugar moiety. Such derivatives and analogs are discussed in, for example, Scheit, Nucleotide Analogs (John Wiley & Son, 1980) and Uhlman et al., Chemical Reviews 90: 543-584, 1990. Nucleotide analogs can also include modified phosphodiester bonds, including phosphorothioate bonds, phosphorodithioate bonds, alkylphosphonate bonds, aniline phosphate bonds and phosphoramidate bonds. As used herein, "derivative", "analog" and "modified" can be used interchangeably, and are covered by the terms "nucleotide" and "nucleoside" defined herein.

[0100] As used herein, the term "phosphate" is used with the ordinary meaning understood by those skilled in the art and includes its protonated form (e.g., ). As used herein, the terms "monophosphate," "diphosphate," and "triphosphate" are used with their ordinary meaning as understood by those skilled in the art, and include protonated forms.

[0101] As used herein, the term "protecting group" refers to any atom or group of atoms added to a molecule in order to prevent existing groups in the molecule from undergoing undesired chemical reactions. Sometimes, "protecting group" and "capping group" can be used interchangeably.

[0102] As used herein, the term "phasing" refers to a phenomenon in SBS, which is caused by the incomplete removal of 3' terminators and fluorophores and the failure to complete the incorporation of a portion of the DNA chain in the cluster by polymerase under a given sequencing cycle. Prephasing is caused by the incorporation of nucleotides that do not have an effective 3' terminator, wherein the incorporation event is advanced by 1 cycle due to termination failure. Phasing and prephasing cause the measured signal intensity of a specific cycle to be composed of the signal from the current cycle and the noise from the previous and next cycles. As the number of cycles increases, the sequence score of each cluster affected by phasing and prephasing increases, hindering the identification of the correct base. Prephasing can be caused by the presence of traces of unprotected or uncapped 3'-OH nucleotides during sequencing by synthesis (SBS). Unprotected 3'-OH nucleotides can be produced during the manufacturing process or may be stored and during the reagent handling process. Therefore, the discovery of nucleotide analogs that reduce the incidence of prephasing is surprising, and provides greater advantages than existing nucleotide analogs in SBS applications. For example, the provided nucleotide analogs can result in faster SBS cycle times, lower phasing and prephasing values, and longer sequencing read lengths.

[0103] Sequencing method using palladium cleavage mixture containing cyclodextrin additive

[0104] Some embodiments of the present disclosure relate to a method for determining the sequence of a plurality of target polynucleotides (e.g., single-stranded polynucleotides), the method comprising:

[0105] (a) contacting a solid support with a spiked mixture comprising a DNA polymerase and one or more of four different types of nucleotides (e.g., dATP, dCTP, dGTP, and dTTP or dUTP) and a sequencing primer that is complementary to and hybridizes to at least a portion of the target polynucleotide, wherein the solid support comprises a plurality of different target polynucleotides immobilized thereon;

[0106] (b) incorporating one type of nucleotide into the sequencing primer to generate an extended copy polynucleotide, wherein each of the four types of nucleotides comprises a 3'

[0107] Capping group;

[0108] (c) imaging the extended copy polynucleotide and performing one or more fluorescence measurements; and

[0109] (d) removing the 3' end of the incorporated nucleotide in an aqueous cleavage solution containing an active palladium catalyst

[0110] Capping group;

[0111] wherein the aqueous cleavage solution comprises one or more additives for improving the thermal or oxidative stability of the active palladium catalyst, and wherein the one or more additives comprise one or more water-soluble macrocycles.

[0112] In some embodiments of the methods described herein, the active palladium catalyst is Pd(0). In some embodiments, the Pd(0) catalyst is formed in situ by a Pd(II) complex and one or more water-soluble phosphines. In some embodiments, the Pd(II) complex comprises [Pd(allyl)Cl]2, Na2PdCl4, K2PdCl4, Li2PdCl4, [Pd(allyl)(THP)]Cl, [Pd(allyl)(THP)2]Cl, Pd(CH3CN)2Cl2, Pd(OAc)2, Pd(PPh3)4, Pd(dba)2, Pd(Acac)2, PdCl2(COD), Pd(TFA)2, Na2PdBr4, K2PdBr4, PdCl2, PdBr2 or Pd(NO3)2, or a combination thereof. In one embodiment, the Pd(II) complex comprises or is [Pd(allyl)Cl]2. In another embodiment, the Pd(II) complex comprises or is Na2PdCl4. In some embodiments, the one or more water-soluble phosphines comprise tri(hydroxypropyl)phosphine (THP), tri(hydroxymethyl)phosphine (THMP), 1,3,5-triaza-7-phosphaadamantane (PTA), bis(p-sulfonylphenyl)phenylphosphine dihydrate potassium salt, tri(carboxyethyl)phosphine (TCEP) or triphenylphosphine-3,3',3"-trisulfonic acid trisodium salt, or a combination thereof. In one embodiment, the one or more water-soluble phosphines comprise or are THP.

[0113] In some embodiments of the methods described herein, the one or more water-soluble macrocycles include or are selected from water-soluble cyclodextrin or its optionally substituted analogs, salts or hydrates. In some embodiments, water-soluble cyclodextrin or its optionally substituted analogs, salts or hydrates include or are selected from β-cyclodextrin, γ-cyclodextrin or its substituted analogs or salts, or combinations thereof. In some such embodiments, the substituted analogs of water-soluble cyclodextrin are independently substituted with one or more substituents, and the one or more substituents are selected from the group consisting of the following items: sulfonate, sulfonate, hydroxyl, carboxyl, succinyl, C1-C6 alkyl, C1-C6 alkyl substituted with sulfonate, sulfonate, carboxyl, carboxylate or hydroxyl, (C1-C6 alkyl)-C (=O)-, or hydroxyl protecting groups (such as-C (=O) CH3 (acetyl) and-C (=O) Ph (benzoyl), or combinations thereof). In other embodiments, the one or more water-soluble cyclodextrins or their substituted analogs, salts or hydrates are selected from the group consisting of sulfonated β-cyclodextrin, (2-hydroxypropyl)-β-cyclodextrin, methyl-β-cyclodextrin, acetyl-β-cyclodextrin, (2-hydroxyethyl)-β-cyclodextrin, triacetyl-β-cyclodextrin, heptath (2,3,6-tri-O-methyl)-β-cyclodextrin, succinyl-β-cyclodextrin, heptath (2,3,6-tri-O-benzoyl)-β-cyclodextrin, carboxymethyl-β-cyclodextrin, β-cyclodextrin hydrate, γ-cyclodextrin hydrate, (2-hydroxypropyl)-γ-cyclodextrin, and salts and combinations thereof. In one embodiment, the one or more water-soluble cyclodextrins include or are selected from sulfonated β-cyclodextrin or its salt (such as sodium or potassium salt). In some other embodiments, the one or more water-soluble macrocycles include or are selected from water-soluble calixarene or its optionally substituted analogs, salts or hydrates. In some further embodiments, the water-soluble calixarene or its optionally substituted analogs, salts or hydrates are selected from the group consisting of: 4-sulfonic calix[4]arene, 4-sulfonic calix[6]arene hydrate and 4-sulfothiacx[4]arene sodium salt, and combinations thereof. In some other embodiments, the one or more water-soluble macrocycles include or are selected from water-soluble cucurbituril or its optionally substituted analogs, salts or hydrates. In some further embodiments, the water-soluble cucurbituril or its optionally substituted analogs, salts or hydrates are selected from the group consisting of: cucurbit[5]uril hydrate, cucurbit[6]uril hydrate, cucurbit[7]uril hydrate and cucurbit[8]uril hydrate, and combinations thereof.In some such embodiments, the substituted analogs of the water-soluble calixarene or cucurbituril may be independently substituted with one or more substituents selected from the group consisting of sulfonate, sulfonate, hydroxyl, carboxyl, succinyl, C1-C6 alkyl, C1-C6 alkyl substituted with sulfonate, sulfonate, carboxyl, carboxylate or hydroxyl, (C1-C6 alkyl)-C(=O)-, or a hydroxyl protecting group (such as -C(=O)CH3 (acetyl) and -C(=O)Ph (benzoyl), or a combination thereof). In some embodiments, the molar ratio of the water-soluble macrocycle (or its analog, salt or hydrate) to the Pd catalyst is about 20:1 to 1:20, about 10:1 to about 1:10, or about 5:1 to about 1:5. For example, the molar ratio of the water-soluble macrocycle (or its analog, salt or hydrate) to the Pd catalyst is about 1: 1, 2: 1, 3: 1, 4: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1 or 10: 1. In one embodiment, the molar ratio of the water-soluble cyclodextrin (or its analog, salt or hydrate) to the Pd catalyst is about 4: 1.

[0114] In some embodiments of the methods described herein, the aqueous lysis solution further comprises one or more oxygen scavengers and / or phosphine reducing agents. In some such embodiments, the one or more oxygen scavengers include or are selected from sodium sulfite, sodium bisulfite, sodium pyrosulfite, or a combination thereof. Other non-limiting examples of oxygen scavengers include ascorbic acid, ascorbate (e.g., sodium sorbate or potassium sorbate), catechol, glucose oxidase, ethanol oxidase, sodium isoascorbate, ethylene-methyl acrylate resin, ferrous carbonate, iron powder + sodium chloride, iron powder + calcium hydroxide, sodium bicarbonate, hydrazine, carbohydrazide, tannic acid, and zeolites (e.g., faujasite) adsorbed with terpenes ((R)-(+)-limonene or D-pinene) or phenol derivatives (thymol, resorcinol, pyrocatechol). In some embodiments, the one or more phosphine reducing agents include or are strychnine. Non-limiting examples of boron-containing phosphine reducing agents include sodium borohydride, borane tetrahydrofuran, lithium borohydride, sodium triacetoxyborohydride, borane dimethylamine, borane dimethyl sulfide, catechol borane, tetrabutylammonium borohydride, borane-ammonia complex, calcium borohydride, magnesium borohydride, potassium borohydride, dichlorophenylborane, calcium borohydride bis(tetrahydrofuran), triethyl potassium borohydride, borane diphenylphosphine complex, dicyclohexyl iodide borane, tetraethylammonium borohydride, dichloro(diisopropylamino)borane, bromodimethylborane, diethylmethoxyborane, dichloromethyldiisopropoxyborane, bromodimethylborane, and monobromoborane methyl sulfide.

[0115] In some embodiments of the methods described herein, the one or more additives in the aqueous cleavage solution prevent or reduce the formation of palladium clusters (e.g., when the Pd cleavage solution is under thermal stress). In some embodiments, the one or more additives in the aqueous cleavage solution prevent or reduce oxidation and / or thermal degradation of the active Pd catalyst (e.g., active Pd(0) species).

[0116] In some embodiments of the methods described herein, the method further comprises (e) washing the solid support with an aqueous washing solution. In some such embodiments, steps (a) to (e) are repeated for at least 50, 100, 150, 200, 250, or 300 cycles to determine the target polynucleotide sequence. In some embodiments, the aqueous washing solution comprises at least one Pd(II) scavenger. In some such embodiments, the washing solution does not comprise lipoic acid or 3,3'-dithiodipropionic acid (DDPA) after cleavage.

[0117] Palladium catalyst

[0118] In some embodiments, the Pd catalyst for removing or cracking the 3' end-capping group described herein is water-soluble. In some such embodiments, the Pd catalyst is in the form of active Pd(0). In some cases, the Pd(0) catalyst can be generated in situ by the reduction of a reagent such as an olefin, an alcohol, an amine, a phosphine, or a metal hydride from a Pd complex or a Pd precatalyst (e.g., a Pd(II) complex). Suitable palladium sources include Pd(CH3CN)2Cl2, [PdCl(allyl)]2, [Pd(allyl) (THP)]Cl, [Pd(allyl) (THP)2]Cl, Pd(OAc)2, Pd(PPh3)4, Pd(dba)2, Pd(Acac)2, PdCl2(COD), Pd(TFA)2, Na2PdBr4, K2PdBr4, PdCl2, PdBr2, and Pd(NO3)2. In one such embodiment, the Pd(0) complex is generated in situ from an organic or inorganic salt of a palladium salt (II), such as Na2PdCl4, K2PdCl4, or Li2PdCl4. In another embodiment, the palladium source is an allylpalladium chloride (II) dimer [(allyl)PdCl]2 or [PdCl(C3H5)]2. In some embodiments, the Pd(0) catalyst is produced in aqueous solution by mixing the Pd(II) complex with a water-soluble phosphine. Suitable phosphines include water-soluble phosphines such as tri(hydroxypropyl)phosphine (THP), tri(hydroxymethyl)phosphine (THMP), 1,3,5-triaza-7-phosphaadamantane (PTA), bis(p-sulfonic acid phenyl)phenylphosphine dihydrate potassium salt, tri(carboxyethyl)phosphine (TCEP), and triphenylphosphine-3,3',3'-trisulfonic acid trisodium salt, or a combination thereof.

[0119] In some embodiments, the palladium catalyst is prepared by mixing [(allyl)PdCl]2 with THP in situ. The molar ratio of [(allyl)PdCl]2 to THP can be about 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:6.5, 1:7, 1:7.5, 1:8, 1:8.5, 1:9, 1:9.5, or 1:10. In one embodiment, the molar ratio of [(allyl)PdCl]2 to THP is 1:10. In some other embodiments, the palladium catalyst is prepared by mixing a water-soluble Pd reagent such as Na2PdCl4 or K2PdCl4 with THP in situ. The molar ratio of Na2PdCl4 or K2PdCl4 to THP may be about 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:6.5, 1:7, 1:7.5, 1:8, 1:8.5, 1:9, 1:9.5, or 1:10. In one embodiment, the molar ratio of Na2PdCl4 or K2PdCl4 to THP is about 1:3. In another embodiment, the molar ratio of Na2PdCl4 or K2PdCl4 to THP is about 1:3.5.

[0120] The Pd complex and water-soluble phosphine used in the cleavage step of the method described herein can be in a composition or mixture, also referred to as a cleavage mixture. In some further embodiments, the cleavage mixture can contain additional buffer reagents, such as primary amines, secondary amines, tertiary amines, natural amino acids, non-natural amino acids, carbonates, phosphates or borates, or combinations thereof. In some further embodiments, the buffer reagents include ethanolamine (EA), tris(hydroxymethyl)aminomethane (Tris), glycine, sodium carbonate, sodium phosphate, sodium borate, dimethylethanolamine (DMEA), diethylethanolamine (DEEA), N,N,N',N'-tetramethylethylenediamine (TMEDA), N,N,N',N'-tetraethylethylenediamine (TEEDA) or piperidinylethanol (having the structure In one embodiment, one or more buffer reagents include DEEA. In another embodiment, the one or more buffer reagents include PipEA. In another embodiment, the one or more buffer reagents contain one or more inorganic salts, such as carbonate, phosphate or borate, or a combination thereof. In one embodiment, the inorganic salt is a sodium salt.

[0121] In some embodiments, the molar ratio of the palladium catalyst to the palladium scavenger comprising one or more allylic moieties is about 1: 100, 1:50, 1:20, 1: 10, or 1: 5. In some additional embodiments, the palladium scavenger comprising one or more allylic moieties is a palladium scavenger of Pd(0), the active form of the Pd catalyst.

[0122] In some embodiments, the cleavage conditions of the 3' blocking group are the same as the conditions for cleaving the cleavable linker of the nucleotide. For example, the nucleotide can include the same linker portion as the 3' blocking group. In other embodiments, the cleavage conditions of the 3' blocking group are different from the conditions for cleaving the cleavable linker of the nucleotide.

[0123] Palladium scavenger

[0124] Certain aspects of the present disclosure relate to employing alternative palladium scavengers in several steps of sequencing by synthesis, wherein at least one palladium scavenger comprises one or more allylic moieties (e.g., -O-allyl, -S-allyl, -NR-allyl, or -N-allyl). + RR'-allyl), or a combination thereof, as a competitive substrate to consume any residual Pd(0) attached to the nucleic acid (i.e., Pd(0) scavengers). These Pd(0) scavengers are described in WO 2022 / 243480, which is incorporated by reference in its entirety. The sequencing methods described herein substantially improve sequencing metrics (e.g., reducing phasing values ​​and prephasing values) and can also reduce sequencing time per cycle by eliminating certain post-cleavage processing steps.

[0125] In some embodiments of any of the methods described herein, a palladium scavenger comprising one or more allyl moieties is in the first aqueous solution. In some cases, the first aqueous solution is also referred to as an incorporation mixture (IMX). In some such embodiments, this palladium scavenger is compatible with other sequencing reagents in the first aqueous solution, and in addition to one or more different types of nucleotides, the first aqueous solution may also include a polymerase (such as a DNA polymerase). In some such embodiments, the polymerase is a DNA polymerase, such as a mutant of a 9°N polymerase (e.g., those disclosed in WO 2005 / 024010, which is incorporated by reference), for example, Pol 812, Pol 1901, Pol 1558, or Pol 963. The amino acid sequences of Pol 812, Pol 1901, Pol 1558, or Pol 963 DNA polymerases are described in, for example, U.S. Patent Publications No. 2020 / 0131484A1 and No. 2020 / 0181587A1, which are incorporated herein by reference. In some embodiments, the first aqueous solution also includes one or more buffers. The buffer may include primary amines, secondary amines, tertiary amines, natural amino acids or non-natural amino acids, or a combination thereof. In other embodiments, the buffer includes ethanolamine or glycine, or a combination thereof. In one embodiment, the buffer includes glycine, or is glycine. In other embodiments, the palladium scavenger comprising one or more allyl moieties does not require a separate washing step before the next incorporation cycle. In other embodiments, the palladium scavenger in the first aqueous solution is a Pd(0) scavenger as described herein. In some embodiments, the Pd(0) scavenger is premixed with one or more of the DNA polymerase and / or four types of nucleotides (e.g., dATP, dCTP, dGTP and dTTP or dUTP). In other embodiments, the Pd(0) scavenger is stored separately from the DNA polymerase and / or one or more of the four types of nucleotides, and is mixed with these components shortly before the sequencing run begins.

[0126] In some embodiments of any of the methods described herein, the concentration of the Pd(0) scavenger comprising one or more allyl moieties in the first aqueous solution is from about 0.1 mM to about 100 mM, from 0.2 mM to about 75 mM, from about 0.5 mM to about 50 mM, from about 1 mM to about 20 mM, or from about 2 mM to about 10 mM. In other embodiments, the concentration of the palladium scavenger (e.g., Pd(0) scavenger) is about 0.1 mM, 0.2 mM, 0.3 mM, 0.4 mM, 0.5 mM, 0.6 mM, 0.7 mM, 0.8 mM, 0.9 mM, 1 mM, 1.5 mM, 2 mM, 2.5 mM, 3 mM, 3.5 mM, 4 mM, 4.5 mM, 5 mM, 5.5 mM, 6 mM, 6.5 mM, 7 mM, 7.5 mM, 8 mM, 8.5 mM, 9 mM, 9.5 mM, 10 mM, 12.5 mM, 15 mM, 17.5 mM, or 20 mM, or a range defined by any two of the foregoing values. In other embodiments, the concentration of the palladium scavenger is the concentration in the first aqueous solution. In other embodiments, the pH of the first aqueous solution is about 9.

[0127] In some other embodiments of any of the methods described herein, a palladium scavenger comprising one or more allyl moieties is in solution when performing one or more fluorescence measurements. In such embodiments, such palladium scavengers are compatible with the sequencing reagents of the scanning solution (also referred to as the scanning mixture). In further embodiments, one or more palladium scavengers do not require a separate washing step prior to the next incorporation cycle. In further embodiments, the palladium scavenger in the scanning solution is a Pd(0) scavenger as described herein.

[0128] In other embodiments of the methods described herein, a palladium scavenger comprising one or more allyl moieties is in the post-cleavage wash solution (i.e., the second aqueous solution). In additional embodiments, the palladium scavenger in the post-cleavage wash solution is a Pd(0) scavenger described herein. In some such embodiments, the post-cleavage wash solution does not comprise lipoic acid or 3,3'-dithiodipropionic acid (DDPA).

[0129] In yet other embodiments of the methods described herein, a palladium scavenger comprising one or more allyl moieties can be present in the first aqueous solution (e.g., incorporated into the mixture) and the second aqueous solution (e.g., post-cleavage wash solution), or in the first aqueous solution and the scanning mixture. In some such embodiments, the post-cleavage wash solution does not comprise lipoic acid or DDPA.

[0130] Non-limiting examples of Pd(0) scavengers comprising one or more -O-allyl or allylic moieties include the following:

[0131] (Compound A), (Compound B, N-BocTyr(allyl)-OH), (Compound C, allyl-bd-glucopyranoside), (Compound D), (Compound E), (Compound F), (Compound G), (Compound H), (Compound I), (Compound J), (Compound K), (Compound L), (Compound M) and (Compound N).

[0132] Non-limiting examples of Pd(0) scavengers comprising one or more -S-allyl moieties include the following:

[0133] Contains one or more –NR-allyl or –N + Non-limiting examples of RR'-allyl moieties of Pd(0) scavengers include the following: Where Z - is an anion (e.g., a halide anion such as F - or Cl - In one embodiment, the palladium scavenger is a palladium scavenger (Compound O, diallyldimethylammonium chloride, also known as DADMAC).

[0134] In some embodiments of the methods described herein, the method may further use additional palladium scavengers, such as Pd (II) scavengers. In some such embodiments, the use of additional Pd scavengers can improve the phasing value of sequencing indicators. For example, additional Pd scavengers may include isocyanoacetic acid (ICNA) salts, ethyl isocyanoacetate, methyl isocyanoacetate, cysteine ​​(e.g., L-cysteine) or its salts (e.g., N-acetyl-L-cysteine), potassium ethyl xanthate, potassium isopropyl xanthate, glutathione, ethylenediaminetetraacetic acid (EDTA), iminodiacetic acid, nitrilodiacetic acid, trithio-S-triazine, dimethyl dithiocarbamate, dithiothreitol, mercaptoethanol, allyl alcohol, propargyl alcohol, thiol, thiosulfate salts (e.g., sodium thiosulfate or potassium thiosulfate), tertiary amines and / or tertiary phosphine or combinations thereof. In one embodiment, the method also includes the use of L-cysteine ​​or its salts. In another embodiment, the method also includes the use of thiosulfate such as sodium thiosulfate (Na2S2O3). In some embodiments, the additional Pd scavenger is a scavenger of Pd (II). In some such embodiments, the Pd (II) scavenger (e.g., L-cysteine ​​or sodium thiosulfate) is in the first aqueous solution. In other embodiments, the Pd (II) scavenger (e.g., L-cysteine ​​or sodium thiosulfate) is in the washing solution (i.e., the second aqueous solution) after cleavage. In other embodiments, the Pd (II) scavenger (e.g., L-cysteine ​​or sodium thiosulfate) may be present in both the first aqueous solution and the second aqueous solution. In other embodiments, the Pd (II) scavenger (e.g., L-cysteine ​​or sodium thiosulfate) may be present in a scanning mixture (i.e., a solution that performs one or more fluorescence measurements of the incorporated nucleotides). In other embodiments, the Pd (II) scavenger may be present in one or more of the incorporation mixture (e.g., the first aqueous solution), the scanning mixture or the washing solution (e.g., the second aqueous solution) after cleavage. In other embodiments, the concentration of the Pd(II) scavenger (such as L-cysteine ​​or sodium thiosulfate) in the first aqueous solution or the second aqueous solution is about 0.1 mM to about 100 mM, 0.2 mM to about 75 mM, about 0.5 mM to about 50 mM, about 1 mM to about 20 mM, or about 2 mM to about 10 mM. In other embodiments, the concentration of the Pd(II) scavenger (such as L-cysteine ​​or sodium thiosulfate) is about 0.1 mM, 0.5 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 6.5 mM, 7 mM, 8 mM, 9 mM, 10 mM, 12.5 mM, 15 mM, 17.5 mM, or 20 mM, or a range defined by any two of the foregoing values. In further embodiments, the Pd(II) scavenger is in the second aqueous solution, and the concentration of the Pd(II) scavenger in the second aqueous solution is about 10 mM.

[0135] In some embodiments of the methods described herein, all Pd scavengers are in the first aqueous solution. In some other embodiments of the methods described herein, all Pd scavengers are in the second aqueous solution. In some other embodiments, one or more Pd scavengers (e.g., Pd(0) scavengers) comprising one or more allyl moieties are in the incorporation mixture (i.e., the first aqueous solution), and the Pd(II) scavenger is in the post-cleavage wash solution (i.e., the second aqueous solution). In another embodiment, the post-cleavage wash solution does not contain lipoic acid or DDPA. In other embodiments, the method does not include a post-cleavage wash step.

[0136] In some embodiments of the methods described herein, the target polynucleotide is fixed to the surface of the substrate. In some other embodiments, the surface comprises a variety of fixed target polynucleotides, such as arrays of different fixed target polynucleotides. In some such embodiments, the substrate includes glass, modified or functionalized glass, plastics, polysaccharides, nylon, nitrocellulose, resins, silica, silicon, modified silicon, carbon, metals, inorganic glass or fiber bundles or combinations thereof. In some other embodiments, the substrate is a flow cell, nanoparticles or beads (such as spherical silica beads, inorganic nanoparticles, magnetic nanoparticles, cadmium base points and cadmium-free points, or beads disclosed in U.S. Publication No. 2021 / 0187470A1, which are incorporated by reference). In one embodiment, the substrate is a flow cell including a patterned nanopore separated by a gap region, and wherein the fixed target polynucleotide resides in the patterned nanopore.

[0137] In some embodiments of any of the methods described herein, the method is performed on an automatic sequencing instrument, and wherein the automatic sequencing instrument comprises two light sources operating at different wavelengths (e.g., about 450 nm to about 460 nm, and about 520 nm to about 540 nm, in particular about 460 nm and about 532 nm). In other embodiments, the automatic sequencing instrument comprises a single light source operating at one wavelength.

[0138] Nucleotides with 3' blocking groups

[0139] Some embodiments of the present disclosure relate to nucleotide molecules comprising a nucleobase, a ribose or deoxyribose moiety and a 3' hydroxyl blocking group. In some embodiments, the 3' hydroxyl blocking group comprises an unsubstituted or substituted allyl moiety, such as having a structure attached to the 3' oxygen of the nucleotide. The 3'-capping group, where R a , R b , R c , R d and R eEach is independently H, halogen, unsubstituted or substituted C1-C6 alkyl or C1-C6 haloalkyl. a , R b , R c , R d and R e Each is H. In some other embodiments, R a and R b Each is H, and R c , R d and R e At least one of is independently halogen (e.g., fluorine, chlorine) or unsubstituted C1-C6 alkyl (e.g., methyl, ethyl, isopropyl, isobutyl or tert-butyl). c is an unsubstituted C1-C6 alkyl group, and R d and R e Each is H. In another example, R c is H, and R d and R e One or both of is halogen or unsubstituted C1-C6 alkyl. Non-limiting embodiments of the 3'-capping group include In one embodiment, the 3' blocking group is It forms with the 3′ oxygen ("AOM") group, the AOM group is connected to the 3' carbon atom of the ribose or deoxyribose moiety. Additional embodiments of the 3' blocking group are disclosed in U.S. Publication No. 2020 / 0216891A1, which is incorporated by reference in its entirety. In any embodiment of the nucleotides described herein, the nucleotide may include a 3' blocked 2-deoxyribose moiety. In addition, the nucleotide may be a nucleoside triphosphate. In another embodiment, the 3' blocking group is an allyl ether group (-O-CH2CH=CH2) connected to the 3' carbon atom of the deoxyribose moiety.

[0140] Labeled nucleotides

[0141] In some embodiments, 3' blocked nucleotides also include detectable labels, and this nucleotide is referred to as labeled nucleotides or fully functionalized nucleotides (WN). Labels (e.g., fluorescent dyes) are conjugated via cleavable joints in a variety of ways, and these ways include hydrophobic attraction, ion attraction, and covalent bonding. In some aspects, dyes are conjugated to nucleotides by covalent bonding realized via cleavable joints. One of ordinary skill in the art understands that the label can be covalently bound to a joint by reacting the functional group (e.g., carboxyl) of the label with the functional group (e.g., amino) of a joint. In some such embodiments, a cleavable joint can include the same part as a 3' blocking group. Therefore, a cleavable joint and a 3' blocking group can be cracked or removed under the same reaction conditions. In some such embodiments, a cleavable joint can include an allyl moiety, specifically a part including the following structure:

[0142] Where R 1a , R 1b , R 2a , R 3a and R 3b Each is independently H, halogen, unsubstituted or substituted C1-C6 alkyl or C1-C6 haloalkyl.

[0143] In some embodiments, the dye can be covalently attached to the oligonucleotide or nucleotide via the nucleotide base. For example, the labeled nucleotide or oligonucleotide can have a label attached to the C5 position of a pyrimidine base or the C7 position of a 7-deazapurine base via a cleavable linker moiety.

[0144] Nucleotide can be marked at the site on sugar or nucleobase.As known in the art, "nucleotide" is composed of nitrogenous base, sugar and one or more phosphate groups.In RNA, the sugar is ribose, and in DNA it is deoxyribose, that is, the sugar lacking the hydroxyl group present in ribose.Nitrogenous base is a derivative of purine (e.g., deazapurine, 7-deazapurine) or pyrimidine.Purine is adenine (A) and guanine (G), and pyrimidine is cytosine (C) and thymine (T), or uracil (U) in the case of RNA.The C-1 atom of deoxyribose is bonded to the N-1 of pyrimidine or the N-9 of purine.Nucleotide is also the phosphate ester of nucleoside, wherein esterification occurs on the hydroxyl group of C-3 or C-5 connected to sugar.Nucleotide is usually monophosphate, diphosphate or triphosphate.

[0145] Although bases are commonly referred to as purines or pyrimidines, it will be appreciated by the skilled artisan that derivatives and analogs that do not alter the ability of a nucleotide or nucleoside to undergo Watson-Crick base pairing are available. "Derivatives" or "analogs" mean compounds or molecules whose core structures are identical or very similar to the core structures of the parent compound, but which have chemical or physical modifications that allow the derived nucleotide or nucleoside to be connected to another molecule, such as different or additional side groups. For example, the base can be a deazapurine. In a specific embodiment, the derivative should be able to undergo Watson-Crick pairing. "Derivatives" and "analogs" also include, for example, synthetic nucleotides or nucleoside derivatives with modified base moieties and / or modified sugar moieties. Such derivatives and analogs are discussed in, for example, Scheit, Nucleotide analogs (John Wiley & Son, 1980) and Uhlman et al., Chemical Reviews 90: 543-584, 1990. Nucleotide analogs may also include modified phosphodiester bonds, including phosphorothioate bonds, phosphorodithioate bonds, alkylphosphonate bonds, aniline phosphonate bonds, phosphoramidite bonds, and the like.

[0146] In a specific embodiment, the nucleotide of the label can be enzymatically incorporable and enzymatically extendable. Therefore, the linker portion can have enough length to connect the nucleotide to the compound so that the compound does not significantly interfere with the overall binding and recognition of the nucleic acid replicator to the nucleotide. Therefore, the linker can also include a spacer unit. The spacer distance is, for example, the distance of the nucleotide base from the cleavage site or label.

[0147] The present disclosure also encompasses polynucleotides incorporating nucleotides described herein. Such polynucleotides may be DNA or RNA composed of deoxyribonucleotides or ribonucleotides joined with phosphodiester bonds, respectively. Polynucleotides may include naturally occurring nucleotides combined with at least one modified nucleotide (e.g., labeled with a dye compound) as shown herein, non-naturally occurring (or modified) nucleotides other than the labeled nucleotides described herein, or any combination thereof. Polynucleotides according to the present disclosure may also include non-natural backbone bonds and / or non-nucleotide chemical modifications. It is also contemplated that a chimeric structure consisting of a mixture of ribonucleotides and deoxyribonucleotides comprising at least one labeled nucleotide.

[0148] In some embodiments, the labeled nucleotides described herein comprise or have the structure of Formula (I):

[0149]

[0150] Wherein B is a nucleobase;

[0151] R4 is H or OH;

[0152] R 5 is an allyl-containing 3'-capping group, such as described herein OR 5 It is phosphoramidite;

[0153] R 6 is H, monophosphate, diphosphate, triphosphate, phosphorothioate, phosphate analog, reactive phosphorus-containing group, or hydroxyl protecting group;

[0154] L is a linker containing an allyl moiety, such as and

[0155] L 1 and L 2 Each is independently an optionally present linker moiety.

[0156] In some embodiments of the nucleotides described herein, R 1a , R 1b , R 2a , R 3a and R 3b Each is H. In other embodiments, R 1a , R 1b , R 2a ,' 3a and R 3b At least one of is halogen (e.g., fluorine, chlorine) or unsubstituted C1-C6 alkyl (e.g., methyl, ethyl, isopropyl, isobutyl or tert-butyl). In some such cases, R 1a and R 1b Each is H, and R 2a , R 3a and R 3b At least one of them is unsubstituted C1-C6 alkyl or halogen (e.g., R 2a is an unsubstituted C1-C6 alkyl group, and R 3a and R 3b Each is H; or R 2a is H, and R 3a and R 3b One or both of are halogen or unsubstituted C1-C6 alkyl). In one embodiment, the cleavable linker or L comprises (“AOL” connector portion).

[0157] In some embodiments of the nucleotides described herein, the nucleobase ("B" in formula (I)) is a purine (adenine or guanine), a deaza purine, or a pyrimidine (e.g., cytosine, thymine, or uracil). In some additional embodiments, the deaza purine is a 7-deaza purine (e.g., 7-deaza adenine or 7-deaza guanine). Non-limiting examples of B include Or their optionally substituted derivatives and analogs. In some other embodiments, the labeled nucleobase comprises the structure

[0158] In some other embodiments of the nucleotides described herein, R in formula (I) 5 is a phosphoramidite. In such embodiments, R 6 is an acid-cleavable hydroxyl protecting group that allows subsequent monomer coupling under automated synthesis conditions.

[0159] In some embodiments of the nucleotides described herein, L 1 exists, and L 1 In some further embodiments, L 1 include In some additional embodiments, the asterisk * indicates L 1 The point of attachment to a nucleobase (eg, C5 for a pyrimidine base, or C7 for a 7-deazapurine base).

[0160] Some additional embodiments of nucleosides or nucleotides described herein include those having Formula (Ia), (Ia'), (Ib), (Ic), (Ic'), or (Id):

[0161]

[0162]

[0163] In some additional embodiments of the nucleotides described herein, L 2 exists, and L 2 include wherein n is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and the phenyl moiety is optionally substituted. In some such embodiments, n is 5, and L 2 The phenyl portion is unsubstituted.

[0164] In any of the nucleotide embodiments described herein, the cleavable linker or L 1 / L 2It may also contain a disulfide moiety or an azide moiety (such as ) or a combination thereof. L 1 or L 2 Additional non-limiting examples of linker moieties in include:

[0165]

[0166] Additional linker moieties are disclosed in WO 2004 / 018493 and U.S. Pub. Nos. 2016 / 0040225 and 2021 / 0403500, both of which are incorporated herein by reference.

[0167] Non-limiting exemplary labeled nucleotides as described herein include:

[0168]

[0169]

[0170] wherein L represents a cleavable linker (optionally including L as described herein 2 ), R represents a ribose or deoxyribose moiety as described above, or a ribose or deoxyribose moiety substituted with one, two or three phosphates at the 5' position.

[0171] In some embodiments, non-limiting exemplary fluorescent dye conjugates are shown below:

[0172]

[0173]

[0174] wherein PG represents a 3′-capping group as described herein; n is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and m is 0, 1, 2, 3, 4, or 5. In one embodiment, —O—PG is AOM. In one embodiment, n is 5. Refers to the point of attachment of the dye to the cleavable linker as a result of the reaction between the amino group of the linker moiety and the carboxyl group of the dye.

[0175] Various fluorescent dyes can be used as detectable labels in the present disclosure, especially those dyes that can be excited by blue light (e.g., about 450nm to about 460nm) or green light (e.g., about 520nm to about 540nm). These dyes can also be referred to as "blue dye" and "green dye" respectively. The example of various types of blue dyes, including but not limited to coumarin dyes, color quinoline dyes and containing double boron heterocyclic compounds, is disclosed in U.S. Publication Nos. 2018 / 0094140, 2018 / 0201981, 2020 / 0277529, 2020 / 0277670, 2021 / 0188832, 2022 / 0195517, 2022 / 0380389 and 2023 / 0313292, each of which is incorporated by reference in its entirety. Examples of green dyes include cyanine or polymethine dyes disclosed in International Publication Nos. WO2013 / 041117, WO2014 / 135221, WO 2016 / 189287, WO2017 / 051201, and WO2018 / 060482A1, each of which is incorporated by reference in its entirety.

[0176] In any of the embodiments of the nucleotides described herein, the nucleotide comprises a 2' deoxyribose moiety (ie, R 4 In certain other aspects, the 2' deoxyribose contains one, two or three phosphate groups at the 5' position of the sugar ring. In certain other aspects, the nucleotides described herein are nucleotide triphosphates (ie, -OR 6 to form triphosphates of formula (I) and (Ia) to (Id).

[0177] Additional embodiments of the present disclosure relate to oligonucleotides or polynucleotides comprising nucleosides or nucleotides described herein. In some such embodiments, the oligonucleotides or polynucleotides are hybridized with a template or a target polynucleotide. In some such embodiments, the template polynucleotide is fixed on a solid support.

[0178] Additional embodiments of the present disclosure relate to solid supports comprising an array of a plurality of immobilized template or target polynucleotides, and at least a portion of such immobilized template or target polynucleotides are hybridized to an oligonucleotide or polynucleotide comprising nucleosides or nucleotides described herein.

[0179] The present application will also be further described with reference to DNA, however the description will also apply to RNA, PNA and other nucleic acids unless otherwise indicated.

[0180] Cleavage conditions for cleavable linkers

[0181] In any embodiment of the nucleotide or nucleoside described herein, the 3' blocking group and the cleavable linker (and the attached label) can be removed under the same or substantially the same chemical reaction conditions, for example, the 3' blocking group and the detectable label can be removed in a single chemical reaction. In other embodiments, the 3' blocking group and the detectable label are removed in two separate steps.

[0182] The cleavable linkers described herein can be removed or cleaved under various chemical conditions. Non-limiting cleavage conditions include palladium catalysts such as Pd(II) complexes (e.g., Pd(OAc)2, allyl palladium chloride (II) dimer [(allyl)PdCl]2 or Na2PdCl4) in the presence of water-soluble phosphine ligands such as tris(hydroxypropyl)phosphine (THP), tris(hydroxymethyl)phosphine and / or tris(2-carboxyethyl)phosphine (TCEP), in the presence or absence of a reducing agent. Non-limiting cleavage conditions include nickel catalysts such as Ni(II) compounds (NiCl2) in the presence of phosphine ligands (e.g., tris(hydroxypropyl)phosphine, tris(hydroxymethyl)phosphine and / or tris(2-carboxyethyl)phosphine). In some embodiments, the 3' capping group can be cleaved under the same or substantially the same cleavage conditions as those used for the cleavable linker.

[0183] Compatible with linearization

[0184] In order to maximize the throughput of nucleic acid sequencing reactions, it is advantageous to be able to sequence multiple template molecules in parallel. Parallel processing of multiple templates can be achieved by using nucleic acid array technology. These arrays are usually composed of a high-density matrix of polynucleotides that are fixed to a solid carrier material.

[0185] WO 98 / 44151 and WO 00 / 18957 have all described nucleic acid amplification methods, and it allows amplification products to be fixed on solid carriers to form arrays, and these arrays are made up of clusters or " colonies ", and wherein clusters or " colonies " are formed by multiple identical immobilized polynucleotide chains and multiple identical immobilized complementary chains. This type of array is referred to as " clustered array " in this article. The nucleic acid molecules present in the DNA colonies on the clustered array prepared according to these methods can provide templates for sequencing reactions, for example as described in WO 98 / 44152. The product of solid phase amplification reaction (such as those described in WO 98 / 44151 and WO 00 / 18957) is a so-called " bridging " structure, and these structures are formed by annealing paired immobilized polynucleotide chains and immobilized complementary chains (both chains are connected to the solid carrier at 5 ' ends). In order to provide a more suitable template for nucleic acid sequencing, it is preferred to remove substantially all or at least a portion of one of the immobilized chains of the " bridging " structure, so as to produce a template that is at least partially single-stranded. Therefore, the single-stranded portion of the template will be available for hybridization with the sequencing primer. The process of removing all or part of an immobilized strand in a "bridging" double-stranded nucleic acid structure is called "linearization". There are many ways of linearization, including but not limited to enzymatic cleavage, photochemical cleavage, or chemical cleavage. Non-limiting examples of linearization methods are disclosed in PCT Publication No. WO 2007 / 010251, U.S. Patent Publication No. 2009 / 0088327, U.S. Patent Publication No. 2009 / 0118128, and U.S. Patent Publication No. 2019 / 0352327, which are incorporated by reference in their entirety.

[0186] In some embodiments, the conditions for removing the 3' blocking group and / or the cleavable linker are also compatible with linearization methods, such as chemical linearization methods involving the use of a Pd complex and a phosphine. In some embodiments, the Pd complex is a Pd(II) complex (e.g., Pd(OAc)2, [(allyl)PdCl]2, or Na2PdCl4) , Pd(0) is generated in situ in the presence of a water-soluble phosphine described herein, in the presence or absence of a reducing agent.

[0187] Sequencing by Synthesis Implementation and Alternatives

[0188] Alternatively, unlabeled nucleotides and affinity reagents containing fluorescent dyes described herein can also be used to carry out sequencing methods described herein. For example, in the incorporation mixture of step (a), one type, two types, three types or each type of four different types of nucleotides (e.g., dATP, dCTP, dGTP and dTTP or dUTP) can be unlabeled. Each type of nucleotide in four types of nucleotides (e.g., dNTP) has a 3' hydroxyl blocking group to ensure that only a single base can be added to the 3' end of the primer polynucleotide by a polymerase. After incorporating unlabeled nucleotides in step (b), the remaining unincorporated nucleotides are washed off. Affinity reagents are then introduced, which specifically recognize and combine the dNTPs incorporated to provide an extension product containing the labeling of the dNTPs incorporated. The use of unlabeled nucleotides and affinity reagents in synthetic sequencing has been disclosed in WO 2018 / 129214 and WO 2020 / 097607. In addition, post-incorporation label sequencing methods have been described in U.S. Publication No. 2023 / 0383342A1 and U.S. Patent Application Serial No. 63 / 579897, each of which is incorporated herein by reference. The modified sequencing method of the present disclosure using unlabeled nucleotides may include the following steps:

[0189] (a') contacting a solid support with a spike-in mixture comprising a DNA polymerase and one or more of four different types of unlabeled nucleotides (e.g., dATP, dCTP, dGTP, and dTTP or dUTP) and a sequencing primer that is complementary to and hybridizes to at least a portion of the target polynucleotide, wherein the solid support comprises a plurality of different target polynucleotides immobilized thereon;

[0190] (b') incorporating one type of nucleotide into the sequencing primer to generate an extended copy polynucleotide, wherein each of the four types of nucleotides comprises a 3'

[0191] Capping group;

[0192] (c') contacting the extended copy polynucleotide with a set of affinity reagents under conditions where one of the affinity reagents specifically binds to the incorporated unlabeled nucleotide to provide a labeled extended copy polynucleotide;

[0193] (d') imaging the solid support and performing one or more fluorescence measurements of the extended copy polynucleotide; and

[0194] (e') removing the 3' blocking group of the incorporated nucleotide;

[0195] Wherein the aqueous cleavage solution comprises one or more additives for improving the thermal or oxidative stability of the active palladium catalyst, and wherein the one or more additives comprise one or more water-soluble macrocycles as described herein. In some embodiments, the additives in the aqueous cleavage solution further comprise one or more oxygen scavengers and / or phosphine reducing agents as described herein.

[0196] In some embodiments of the modified sequencing method described herein, the method also includes removing the affinity reagent from the incorporated nucleotides. In other additional embodiments, the 3' hydroxyl blocking group and the affinity reagent are removed in the same reaction. In some embodiments, the method also includes step (f') washing the solid support with an aqueous washing solution. In other embodiments, steps (a') to (f') are repeated for at least 50, 100, 150, 200, 250 or 300 cycles to determine the target polynucleotide sequence. In some embodiments, the affinity reagent group may include a first affinity reagent that specifically binds to the first type of nucleotides, a second affinity reagent that specifically binds to the second type of nucleotides, and a third affinity reagent that specifically binds to the third type of nucleotides. In some additional embodiments, each of the first affinity reagent, the second affinity reagent, and the third affinity reagent includes a spectrally distinguishable detectable label. In some embodiments, the affinity reagent may include a protein tag, an antibody (including but not limited to a binding fragment of an antibody, a single-chain antibody, a bispecific antibody, etc.), an aptamer, a knotting element, an affimer, or any other known reagent that binds to the incorporated nucleotides with suitable specificity and affinity. In one embodiment, at least one affinity reagent is an antibody or a protein tag. In another embodiment, at least one of the first type of affinity reagent, the second type of affinity reagent, and the third type of affinity reagent is an antibody or a protein tag comprising one or more detectable labels (e.g., multiple copies of the same detectable label), wherein the detectable label is or includes a biboron dye moiety as described herein.

[0197] Some embodiments include pyrophosphate sequencing technology. Pyrophosphate sequencing detects the release of inorganic pyrophosphate (PPi) when a specific nucleotide is incorporated into a nascent chain (Ronaghi, M., Karamohamed, S., Pettersson, B., Uhlen, M., and Nyren, P. (1996), "Real-time DNA sequencing using detection of pyrophosphate release.", Analytical Biochemistry 242 (1), 84-9; Ronaghi, M. (2001) "Pyrosequencing sheds light on DNA sequencing" Genome Res. 11 (1), 3-11; Ronaghi, M., Uhlen, M., and Nyren, P. (1998) "A sequencing method based on real-time pyrophosphate." Science 281 (5375), 363; U.S. Pat. Nos. 6,210,891, 6,258,568 and 6,274,320, the disclosures of which are incorporated herein by reference in their entirety). In pyrophosphate sequencing, the released PPi can be detected by being immediately converted into ATP by adenosine triphosphate (ATP) sulfurylase, and the level of ATP generated is detected by photons generated by luciferase. The nucleic acid to be sequenced can be attached to a feature in an array, and the array can be imaged to capture the chemiluminescent signal generated by the incorporation of nucleotides at the feature of the array. The image can be obtained after treating the array with a specific nucleotide type (e.g., A, T, C or G). The images obtained after adding each nucleotide type will differ in which features in the array are detected. These differences in the image reflect the different sequence contents of the features on the array. However, the relative position of each feature will remain unchanged in the image. The images can be stored, processed and analyzed using the methods described herein. For example, images obtained after treating the array with each different nucleotide type can be processed in the same manner as exemplified herein for images obtained from different detection channels for a reversible terminator-based sequencing method.

[0198] In another exemplary type of SBS, cycle sequencing is accomplished by stepwise addition of reversible terminator nucleotides comprising, for example, cleavable or photobleachable dye labels, as described, for example, in WO 04 / 018497 and U.S. Pat. No. 7,057,026, the disclosures of which are incorporated herein by reference. This method is commercialized by Solexa (now Illumina, Inc.) and is also described in WO 91 / 06678 and WO 07 / 123,744, each of which is incorporated herein by reference. The availability of fluorescently labeled terminators, in which not only termination can be reversed but also the fluorescent label can be cleaved, facilitates efficient cyclic reversible termination (CRT) sequencing. Polymerases can also be co-engineered to efficiently incorporate and extend from these modified nucleotides.

[0199] Preferably, in the sequencing embodiment based on reversible terminator, the label does not substantially inhibit extension under SBS reaction conditions. However, the detection label can be removable, such as removed by cleavage or degradation. Images can be captured after the label is incorporated into the arrayed nucleic acid feature. In a specific embodiment, each cycle involves four different nucleotide types being delivered to the array simultaneously, and each nucleotide type has a label that is spectrally different. Four images can then be obtained, each image using a detection channel that is selective to one label in the four different labels. Alternatively, different nucleotide types can be added sequentially, and the image of the array can be obtained between each addition step. In such embodiments, each image will show the nucleic acid feature of the nucleotide that has been incorporated with a specific type. Due to the different sequence content of each feature, different feature will be present or not present in different images. However, the relative position of the feature will remain unchanged in the image. The image obtained by such reversible terminator-SBS method can be stored, processed and analyzed as described herein. After the image capture step, the label can be removed, and the reversible terminator part can be removed, so that the subsequent cycle of nucleotide addition and detection can be performed. Removing labels after they have been detected in a particular cycle and before subsequent cycles can provide the advantage of reducing background signal and crosstalk between cycles. Examples of useful labeling and removal methods are set forth below.

[0200] Some embodiments can use the detection of four different nucleotides using less than four different marks.For example, the method and system described in the material of the combined U.S. Patent Publication No. 2013 / 0079232 can be used to perform SBS.As a first example, a pair of nucleotide types can be detected at the same wavelength, but based on the intensity difference of a member in the pair relative to another member, or based on a member in the pair causing a change (for example, by chemical modification, photochemical modification or physical modification) that a signal that is obvious compared with the signal of another member of the pair detected appears or disappears.As a second example, three of the four different nucleotide types can be detected under specific conditions, and the fourth nucleotide type lacks a mark (for example, the minimum detection caused by background fluorescence, etc.) that can be detected under those conditions or detected minimally under those conditions.The first three nucleotide types can be determined to be incorporated into nucleic acid based on the existence of its corresponding signal, and the fourth nucleotide type can be determined to be incorporated into nucleic acid based on the absence of any signal or the minimum detection of any signal.As a third example, a nucleotide type can include a mark detected in two different channels, and other nucleotide types are detected in no more than one channel. The three exemplary configurations described above are not considered mutually exclusive and can be used in various combinations. An exemplary embodiment combining all three examples is a fluorescence-based SBS method that uses a first nucleotide type detected in a first channel (e.g., dATP with a label detected in the first channel when excited by a first excitation wavelength), a second nucleotide type detected in a second channel (e.g., dCTP with a label detected in the second channel when excited by a second excitation wavelength), a third nucleotide type detected in both the first channel and the second channel (e.g., dTTP with at least one label detected in both channels when excited by the first excitation wavelength and / or the second excitation wavelength), and a fourth nucleotide type that lacks a label detected or minimally detected in either channel (e.g., dGTP without a label).

[0201] In addition, as described in the materials of the incorporated U.S. publication 2013 / 0079232, a single channel can be used to obtain sequencing data. In such so-called single dye sequencing methods, a first nucleotide type is marked, but the mark is removed after the first image is generated, and a second nucleotide type is marked only after the first image is generated. A third nucleotide type retains its mark in both the first and second images, and a fourth nucleotide type remains unmarked in both images.

[0202] Some embodiments can utilize sequencing technology while connecting. Such technology utilizes DNA ligase to incorporate oligonucleotides and recognize the incorporation of such oligonucleotides. Oligonucleotides generally have different labels related to the identity of specific nucleotides in the sequence to which the oligonucleotides hybridize. As with other SBS methods, images can be obtained after the array of nucleic acid features is treated with labeled sequencing reagents. Each image will show the nucleic acid features into which a specific type of label has been incorporated. Due to the different sequence content of each feature, different features will be present or absent in different images, but the relative position of the features will remain unchanged in the image. Images obtained by sequencing methods based on connection can be stored, processed and analyzed as described herein. Exemplary SBS systems and methods that can be used with the methods and systems described herein are described in U.S. Patent Nos. 6,969,488, 6,172,218 and 6,306,597, and the disclosures of these patents are incorporated herein by reference in their entirety.

[0203] Some embodiments may utilize nanopore sequencing (Deamer, DW and Akeson, M. "Nanopores and nucleic acids: prospects for ultrarapid sequencing." Trends Biotechnol. 18, 147-151 (2000); Deamer, D. and D. Branton, "Characterization of nucleic acids by nanopore analysis," Acc. Chem. Res. 35: 817-825 (2002); Li, J., M. Gershow, D. Stein, E. Brandin and JA Golovchenko, "DNA molecules and configurations in a solid-state nanopore microscope" Nat. Mater. 2: 611-615 (2003), the disclosures of which are incorporated herein by reference in their entirety). In such embodiments, the target nucleic acid passes through a nanopore. The nanopore may be a synthetic pore or a biological membrane protein, such as α-hemolysin. As the target nucleic acid passes through the nanopore, each base pair can be identified by measuring the fluctuations in the conductivity of the pore. (U.S. Pat. No. 7,001,792; Soni, GV and Meller, "A. Progress toward ultrafast DNA sequencing using solid-state nanopores," Clin. Chem., 53, 1996-2001 (2007); Healy, K. "Nanopore-based single-molecule DNA analysis," Nanomed. 2, 459-481 (2007); Cockroft, SL, Chu, J., Amorin, M. and Ghadiri, MR "A single-molecule nanopore device detects DNA polymerase activity with single-nucleotide resolution," J. Am. Chem. Soc. 130, 818-820 (2008), the disclosures of which are incorporated herein by reference in their entirety). The data obtained from nanopore sequencing can be stored, processed and analyzed as described herein. In particular, according to the exemplary processing of optical images and other images described herein, the data may be processed as if it were an image.

[0204] Some other embodiments of the sequencing method relate to the use of 3'-terminated nucleotides described herein in nanoball sequencing technology, such as those described in U.S. Patent No. 9,222,132, the disclosure of which is incorporated herein by reference. A large number of discrete DNA nanoballs can be produced by a rolling circle amplification (RCA) process. The nanoball mixture is then distributed on a patterned glass slide surface containing features that allow a single nanoball to be associated with each position. During the DNA nanoball production process, the DNA is fragmented and then connected to the first of the four adapter sequences. The template is amplified, circularized, and then cleaved with a type II endonuclease. A second set of adapters is added, followed by amplification, circularization, and cleavage. The process is repeated for the remaining two adapters. The final product is a circular template with four adapters, each of which is separated by a template sequence. The library molecules undergo a rolling circle amplification step to produce a large number of concatemers called DNA nanoballs, which are then deposited on a flow cell. Goodwin et al., “Coming of age: ten years of next-generation sequencing technologies,” Nat Rev Genet. 2016;17(6):333-51.

[0205] Some embodiments may utilize methods involving real-time monitoring of DNA polymerase activity. Nucleotide incorporation may be detected by fluorescence resonance energy transfer (FRET) interactions between a polymerase carrying a fluorophore and a γ-phosphate labeled nucleotide (as described, for example, in U.S. Pat. Nos. 7,329,492 and 7,211,414, both of which are incorporated herein by reference), or may be detected with a zero-mode waveguide (as described, for example, in U.S. Pat. No. 7,315,019, which is incorporated herein by reference), and may be detected using fluorescent nucleotide analogs and engineered polymerases (as described, for example, in U.S. Pat. No. 7,405,281 and U.S. Patent Publication No. 2008 / 0108082, both of which are incorporated herein by reference). Illumination can be limited to the z-scale volume around the surface-tethered polymerase, allowing the incorporation of fluorescently labeled nucleotides to be observed with low background (Levene, MJ et al., "Zero-mode waveguides for single-molecule analysis at high concentrations," Science 299, 682-686 (2003); Lundquist, PM et al., "Parallel confocal detection of single molecules in real time," Opt. Lett. 33, 1026-1028 (2008); Korlach, J. et al., "Selective aluminum passivation for targeted immobilization of single DNA polymerase molecules in zero-mode waveguide nano structures." Natl. Acad. Sci. USA 105, 1176-1181 (2008), the disclosures of which are incorporated herein by reference in their entirety). Images obtained by such methods can be stored, processed, and analyzed as described herein.

[0206] Some SBS embodiments include detecting the proton released when nucleotides are incorporated into extension products. For example, sequencing based on the detection of the released proton can use the commercially available electrical detectors and related technologies from Ion Torrent (Guilford, CT, Life Technologies subsidiary), or the sequencing methods and systems described in U.S. Patent Publication Nos. 2009 / 0026082, 2009 / 0127589, 2010 / 0137143 and 2010 / 0282617 (all of these patent publications are incorporated herein by reference). The method for amplifying target nucleic acids using kinetic exclusion set forth herein can be easily applied to substrates for detecting protons. More specifically, the method set forth herein can be used to produce amplicon clone populations for detecting protons.

[0207] The above-mentioned SBS method can be advantageously carried out in a variety of formats so that a plurality of different target nucleic acids are manipulated simultaneously. In a specific embodiment, different target nucleic acids can be processed in a common reaction vessel or on the surface of a specific substrate. This allows to conveniently deliver sequencing reagents, remove unreacted reagents and detect incorporation events in a variety of ways. In the embodiment using the target nucleic acid of surface binding, the target nucleic acid can be an array format. In the array format, the target nucleic acid can be attached to the surface in a spatially distinguishable manner generally. The target nucleic acid can be attached by direct covalent attachment, attached to beads or other particles or attached to a polymerase or other molecules attached to the surface to combine. The array can include a single copy of the target nucleic acid at each site (also referred to as a feature portion), or multiple copies with the same sequence can be present at each site or feature portion. Multiple copies can be produced by an amplification method (such as bridge amplification or emulsion PCR as described in further detail below).

[0208] The methods described herein may use arrays having features at any of a variety of densities, including, for example, at least about 10 features / cm 2 , 100 features / cm 2 , 500 features / cm 2 , 1,000 features / cm 2 , 5,000 features / cm 2 , 10,000 features / cm 2 , 50,000 features / cm 2 , 100,000 features / cm 2 , 1,000,000 features / cm 2 , 5,000,000 features / cm 2 or higher.

[0209] The advantage of the method described herein is that they provide rapid and effective detection of multiple target nucleic acids in parallel. Therefore, the present disclosure provides an integrated system that can use technology known in the art (such as those illustrated above) to prepare and detect nucleic acids. Therefore, the integrated system of the present disclosure may include a fluid assembly that can deliver amplification reagents and / or sequencing reagents to one or more fixed DNA fragments, and the system includes components such as pumps, valves, reservoirs, fluid pipelines, etc. The circulation cell can be configured for and / or for detecting target nucleic acids in the integrated system. Exemplary circulation cells are described in, for example, U.S. Patent Publication No. 2010 / 0111768 and U.S. Patent Application No. 13 / 273,666, each of which is incorporated herein by reference. As illustrated for the circulation cell, one or more fluid assemblies of the integrated system can be used for amplification method and detection method. Taking nucleic acid sequencing embodiment as an example, one or more fluid assemblies of the integrated system can be used for the amplification method described herein and for delivering sequencing reagents in sequencing method (such as those illustrated above). Alternatively, the integrated system may include a separate fluid system to perform amplification method and perform detection method. Examples of integrated sequencing systems that can generate amplified nucleic acids and also determine nucleic acid sequences include, but are not limited to, MiSeq TM The ELISA platform (Illumina, Inc., San Diego, CA), and the apparatus described in U.S. Patent Application No. 13 / 273,666, which is incorporated herein by reference.

[0210] The array that wherein polynucleotide has been directly connected to the carrier based on silica is for example disclosed in WO 00 / 06770 (incorporated herein by reference), wherein polynucleotide is fixed on the glass carrier by the reaction between the epoxy side group on the glass and the internal amino group on the polynucleotide.In addition, polynucleotide can be connected to the solid carrier by the reaction of sulfenyl nucleophilic substance and solid carrier, for example, as described in WO 2005 / 047301 (incorporated herein by reference).Another example of the template polynucleotide of solid support is, wherein template polynucleotide is connected to the hydrogel on the solid support based on silica or other solid supports, for example, as described in WO 00 / 31148, WO 01 / 01143, WO02 / 12566, WO 03 / 014392, U.S. Patent number 6,465,178 and WO 00 / 53812, these patents are separately incorporated herein by reference.

[0211] The specific surface on which the template polynucleotide can be fixed is a polyacrylamide hydrogel. Polyacrylamide hydrogels are described in the references cited above and WO 2005 / 065814, which is incorporated herein by reference. Specific hydrogels that can be used include those described in WO 2005 / 065814 and U.S. Publication 2014 / 0079923. In one embodiment, the hydrogel is PAZAM (poly (N- (5-azidoacetamidopentyl) acrylamide-co-acrylamide)).

[0212] The DNA template molecule can be attached to a bead or microparticle, for example, as described in U.S. Pat. No. 6,172,218 (incorporated herein by reference). The attachment to a bead or microparticle can be used for sequencing applications. A bead library can be prepared, wherein each bead contains a different DNA sequence. Exemplary libraries and methods for their generation are described in the following documents: Nature, 437, 376-380 (2005); Science, 309, 5741, 1728-1732 (2005), each of which is incorporated herein by reference. It is within the scope of the present disclosure to sequence an array of such beads using the nucleotides shown herein.

[0213] The template to be sequenced can form part of an "array" on a solid support, in which case the array can take any convenient form. Therefore, the method of the present disclosure is applicable to all types of high-density arrays, including single-molecule arrays, clustered arrays, and bead arrays. The labeled nucleotides disclosed herein can be used to sequence templates on substantially any type of array (including but not limited to those formed by fixing nucleic acid molecules on a solid support).

[0214] However, the labeled nucleotides of the present disclosure are particularly advantageous in the context of sequencing clustered arrays. In clustered arrays, different regions (commonly referred to as sites or features) on the array include multiple polynucleotide template molecules. Generally speaking, the multiple polynucleotide molecules can not be distinguished individually by optical means, but are detected as a whole. Depending on the formation mode of the array, each site on the array can include multiple copies of a single polynucleotide molecule (for example, the site is homogeneous for a specific single-stranded nucleic acid species or double-stranded nucleic acid species) or even a small amount of multiple copies of different polynucleotide molecules (for example, multiple copies of two different nucleic acid species). The clustered array of nucleic acid molecules can be produced using technology known in the art. By way of example, WO 98 / 44151 and WO 00 / 18957 (each of which is incorporated herein) describe a method for amplifying nucleic acids, wherein template and amplification product are both kept fixed on a solid support to form an array consisting of a cluster or " colony" of fixed nucleic acid molecules. Nucleic acid molecules present on clustered arrays prepared according to these methods are suitable templates for sequencing using nucleotides labeled with the dye compounds of the present disclosure.

[0215] Labeled nucleotides disclosed herein can also be used to sequence the template on a single molecule array. The term "single molecule array" or "SMA" as used herein refers to a group of polynucleotide molecules distributed (or arranged) on a solid support, wherein the spacing between any single polynucleotide and all other polynucleotides of the group makes it possible to distinguish the single polynucleotide molecules individually. Therefore, in some embodiments, the target nucleic acid molecules fixed to the surface of the solid support can be distinguished by optical means. This means that one or more different signals (each signal represents a polynucleotide) will appear in the distinguishable region of the specific imaging device used.

[0216] Single molecule detection can be achieved, wherein the spacing between adjacent polynucleotide molecules on the array is at least 100 nm, more specifically at least 250 nm, more specifically at least 300 nm, and even more specifically at least 350 nm. Therefore, each molecule can be individually resolved and detected as a single molecule fluorescent spot, and the fluorescence from the single molecule fluorescent spot also exhibits single-step photobleaching.

[0217] The terms "individually resolved" and "individually resolved" are used herein to specify that, when visualized, it is possible to distinguish a molecule on an array from its adjacent molecules. The spacing between the individual molecules on the array will be determined in part by the specific techniques used to resolve the individual molecules. The general characteristics of single molecule arrays will be understood by reference to published applications WO 00 / 06770 and WO 01 / 57248, each of which is incorporated herein by reference. Although one use of the nucleotides of the present disclosure is for sequencing reactions while synthesizing, the effectiveness of these nucleotides is not limited to such methods. In fact, these nucleotides can be advantageously used in any sequencing method that requires detection of fluorescent labels attached to nucleotides incorporated into the polynucleotides.

[0218] In particular, the labeled nucleotides disclosed herein can be used in automated fluorescent sequencing protocols, especially fluorescent dye-terminator cycle sequencing based on the chain termination sequencing method of Sanger and colleagues. Such methods typically use enzymes and cycle sequencing to incorporate fluorescently labeled dideoxynucleotides into primer extension sequencing reactions. The so-called Sanger sequencing method and related protocols (Sanger-type) utilize randomized chain termination of labeled dideoxynucleotides.

[0219] Thus, the present disclosure also encompasses labeled nucleotides that are dideoxynucleotides lacking hydroxyl groups at both the 3' and 2' positions, such dideoxynucleotides being suitable for use in Sanger-type sequencing methods and the like.

[0220] It will be appreciated that the labeled nucleotides of the present disclosure incorporating a 3' blocking group may also be used in Sanger methods and related protocols, since the same effect as that achieved by using dideoxy nucleotides may be achieved by using nucleotides having a 3'-OH blocking group: both prevent incorporation of subsequent nucleotides. In cases where nucleotides according to the present disclosure and having a 3' blocking group are to be used in Sanger-type sequencing methods, it will be appreciated that the dye compound or detectable label attached to the nucleotide does not need to be attached via a cleavable linker, since in each case where a labeled nucleotide of the present disclosure is incorporated; no subsequent incorporation of a nucleotide is required, and therefore no removal of the label from the nucleotide is required.

[0221] Method for improving the stability of Pd pyrolysis mixture

[0222] Another aspect of the present disclosure relates to a method for improving the stability of a composition comprising an active palladium catalyst, the method comprising: mixing an aqueous composition comprising a Pd(0) catalyst with one or more additives for improving the thermal or oxidative stability of the active palladium catalyst, and wherein the one or more additives comprise one or more water-soluble macrocycles.

[0223] In some embodiments of the methods described herein, the Pd(0) catalyst is formed in situ from a Pd(II) complex and one or more water-soluble phosphines. In some embodiments, the Pd(II) complex comprises [Pd(allyl)Cl]2, Na2PdCl4, K2PdCl4, Li2PdCl4, [Pd(allyl)(THP)]Cl, [Pd(allyl)(THP)2]Cl, Pd(CH3CN)2Cl2, Pd(OAc)2, Pd(PPh3)4, Pd(dba)2, Pd(Acac)2, PdCl2(COD), Pd(TFA)2, Na2PdBr4, K2PdBr4, PdCl2, PdBr2 or Pd(NO3)2, or a combination thereof. In one embodiment, the Pd(II) complex comprises or is [Pd(allyl)Cl]2. In another embodiment, the Pd(II) complex comprises or is Na2PdCl4. In some embodiments, the one or more water-soluble phosphines include tri(hydroxypropyl)phosphine (THP), tri(hydroxymethyl)phosphine (THMP), 1,3,5-triaza-7-phosphaadamantane (PTA), bis(p-sulfonatophenyl)phenylphosphine dihydrate potassium salt, tri(carboxyethyl)phosphine (TCEP) or triphenylphosphine-3,3',3"-trisulfonic acid trisodium salt, or combinations thereof. In one embodiment, the one or more water-soluble phosphines include or are THP.

[0224] In some embodiments of the methods described herein, the one or more water-soluble macrocycles include water-soluble cyclodextrin or its optionally substituted analogs, salts or hydrates. In some such embodiments, water-soluble cyclodextrin or its analogs, salts or hydrates include or are selected from β-cyclodextrin, γ-cyclodextrin or its substituted analogs or salts, or combinations thereof. In some such embodiments, the substituted analogs of water-soluble cyclodextrin are independently substituted with one or more substituents, and the one or more substituents are selected from the group consisting of the following items: sulfonate, sulfonic, hydroxyl, carboxyl, succinyl, C1-C6 alkyl, C1-C6 alkyl substituted with sulfonic, sulfonic, carboxyl, carboxylate or hydroxyl, (C1-C6 alkyl)-C (=O)-, or hydroxyl protecting groups (such as-C (=O) CH3 (acetyl) and-C (=O) Ph (benzoyl), and combinations thereof). In other embodiments, the one or more water-soluble cyclodextrins or their substituted analogs, salts or hydrates are selected from the group consisting of sulfonated β-cyclodextrin, (2-hydroxypropyl)-β-cyclodextrin, methyl-β-cyclodextrin, acetyl-β-cyclodextrin, (2-hydroxyethyl)-β-cyclodextrin, triacetyl-β-cyclodextrin, heptath (2,3,6-tri-O-methyl)-β-cyclodextrin, succinyl-β-cyclodextrin, heptath (2,3,6-tri-O-benzoyl)-β-cyclodextrin, carboxymethyl-β-cyclodextrin, β-cyclodextrin hydrate, γ-cyclodextrin hydrate, (2-hydroxypropyl)-γ-cyclodextrin, and salts and combinations thereof. In one embodiment, the one or more water-soluble cyclodextrins include or are selected from sulfonated β-cyclodextrin or its salt (such as sodium or potassium salt). In some other embodiments, the one or more water-soluble macrocycles include or are selected from water-soluble calixarene or its optionally substituted analogs, salts or hydrates. In some further embodiments, the water-soluble calixarene or its optionally substituted analogs, salts or hydrates are selected from the group consisting of: 4-sulfonic calix[4]arene, 4-sulfonic calix[6]arene hydrate and 4-sulfothiacx[4]arene sodium salt, and combinations thereof. In some other embodiments, the one or more water-soluble macrocycles include or are selected from water-soluble cucurbituril or its optionally substituted analogs, salts or hydrates. In some further embodiments, the water-soluble cucurbituril or its optionally substituted analogs, salts or hydrates are selected from the group consisting of: cucurbit[5]uril hydrate, cucurbit[6]uril hydrate, cucurbit[7]uril hydrate and cucurbit[8]uril hydrate, and combinations thereof.In some such embodiments, the substituted analogs of the water-soluble calixarene or cucurbituril may be independently substituted with one or more substituents selected from the group consisting of sulfonate, sulfonate, hydroxyl, carboxyl, succinyl, C1-C6 alkyl, C1-C6 alkyl substituted with sulfonate, sulfonate, carboxyl, carboxylate or hydroxyl, (C1-C6 alkyl)-C(=O)-, or a hydroxyl protecting group (such as -C(=O)CH3 (acetyl) and -C(=O)Ph (benzoyl), or a combination thereof). In some embodiments, the molar ratio of the water-soluble macrocycle (or its analog, salt or hydrate) to the Pd catalyst is about 20:1 to 1:20, about 10:1 to about 1:10, or about 5:1 to about 1:5. For example, the molar ratio of the water-soluble macrocycle (or its analog, salt or hydrate) to the Pd catalyst is about 1: 1, 2: 1, 3: 1, 4: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1 or 10: 1. In one embodiment, the molar ratio of the water-soluble cyclodextrin (or its analog, salt or hydrate) to the Pd catalyst is about 4: 1.

[0225] In some embodiments of the methods described herein, the aqueous composition further comprises one or more oxygen scavengers and / or phosphine reducing agents. In some such embodiments, the one or more oxygen scavengers include or are selected from sodium sulfite, sodium bisulfite, sodium pyrosulfite, or a combination thereof. Other non-limiting examples of oxygen scavengers include ascorbic acid, ascorbate (e.g., sodium sorbate or potassium sorbate), catechol, glucose oxidase, ethanol oxidase, sodium isoascorbate, ethylene-methyl acrylate resin, ferrous carbonate, iron powder + sodium chloride, iron powder + calcium hydroxide, sodium bicarbonate, hydrazine, carbohydrazide, tannic acid, and zeolites (e.g., faujasite) adsorbed with terpenes ((R)-(+)-limonene or D-pinene) or phenol derivatives (thymol, resorcinol, pyrocatechol). In some embodiments, the one or more phosphine reducing agents include or are strychnine. Non-limiting examples of boron-containing phosphine reducing agents include sodium borohydride, borane tetrahydrofuran, lithium borohydride, sodium triacetoxyborohydride, borane dimethylamine, borane dimethyl sulfide, catechol borane, tetrabutylammonium borohydride, borane-ammonia complex, calcium borohydride, magnesium borohydride, potassium borohydride, dichlorophenylborane, calcium borohydride bis(tetrahydrofuran), triethyl potassium borohydride, borane diphenylphosphine complex, dicyclohexyl iodide borane, tetraethylammonium borohydride, dichloro(diisopropylamino)borane, bromodimethylborane, diethylmethoxyborane, dichloromethyldiisopropoxyborane, bromodimethylborane, and monobromoborane methyl sulfide.

[0226] In some embodiments of the methods described herein, the one or more additives in the aqueous composition prevent or reduce the formation of palladium clusters (e.g., when the Pd cleavage solution is under thermal stress). In some embodiments, the one or more additives in the aqueous composition prevent or reduce oxidation and / or thermal degradation of the active Pd catalyst (e.g., active Pd(0) species).

[0227] In any embodiments of the methods described herein, the addition of one or more additives (e.g., a water-soluble macrocycle or analog thereof, salt or hydrate thereof, an oxygen scavenger, or a phosphine reducing agent described herein) can improve the thermal and / or oxidative stability of the aqueous Pd cleavage mixture by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, or 200% compared to the same Pd cleavage mixture under the same test conditions over a period of time (e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 14 months, 16 months, 18 months, 20 months, 22 months, or 24 months). In some embodiments, the improvement in thermal and / or oxidative stability is measured by the percentage of residual Pd(0) species (e.g., the percentage of cleavage of the 3' capping group of the nucleotide). Alternatively or in addition, the improvement in thermal stability can also be measured by the formation of Pd clusters in the cleavage solution over a period of time under thermal stress, for example, measured by dynamic light scattering (DLS) data.

[0228] Reagent test kit

[0229] The present disclosure also provides a kit for use with a sequencing device, the kit comprising: an aqueous lysis mixture, the aqueous lysis mixture comprising an aqueous lysis mixture containing an active Pd(0) catalyst; and one or more additives for improving the thermal or oxidative stability of the active Pd(0) catalyst, and wherein the one or more additives comprise one or more water-soluble macrocycles.

[0230] In some embodiments of the methods described herein, the Pd(0) catalyst is formed in situ from a Pd(II) complex and one or more water-soluble phosphines. In some embodiments, the Pd(II) complex comprises [Pd(allyl)Cl]2, Na2PdCl4, K2PdCl4, Li2PdCl4, [Pd(allyl)(THP)]Cl, [Pd(allyl)(THP)2]Cl, Pd(CH3CN)2Cl2, Pd(OAc)2, Pd(PPh3)4, Pd(dba)2, Pd(Acac)2, PdCl2(COD), Pd(TFA)2, Na2PdBr4, K2PdBr4, PdCl2, PdBr2 or Pd(NO3)2, or a combination thereof. In one embodiment, the Pd(II) complex comprises or is [Pd(allyl)Cl]2. In another embodiment, the Pd(II) complex comprises or is Na2PdCl4. In some embodiments, the one or more water-soluble phosphines include tris(hydroxypropyl)phosphine (THP), tris(hydroxymethyl)phosphine (THMP), 1,3,5-triaza-7-phosphaadamantane (PTA), bis(p-sulfonylphenyl)phenylphosphine dihydrate potassium salt, tris(carboxyethyl)phosphine (TCEP) or triphenylphosphine-3,3',3"-trisulfonic acid trisodium salt, or a combination thereof. In one embodiment, the one or more water-soluble phosphines include or are THP. The Pd cleavage mixture may contain an additional buffer, as described above in conjunction with the sequencing method.

[0231] In some embodiments of the kit described herein, the one or more water-soluble macrocycles include water-soluble cyclodextrin or its optionally substituted analog, salt or hydrate. In some such embodiments, water-soluble cyclodextrin or its analog, salt or hydrate include or are selected from β-cyclodextrin, γ-cyclodextrin or its substituted analog or salt, or a combination thereof. In some such embodiments, the substituted analog of water-soluble cyclodextrin is independently substituted by one or more substituents, and the one or more substituents are selected from the group consisting of the following items: sulfonate, sulfonate, hydroxyl, carboxyl, succinyl, C1-C6 alkyl, C1-C6 alkyl substituted by sulfonate, sulfonate, carboxyl, carboxylate or hydroxyl, (C1-C6 alkyl)-C (=O)-, or hydroxyl protecting groups (such as-C (=O) CH3 (acetyl) and-C (=O) Ph (benzoyl)). In other embodiments, the one or more water-soluble cyclodextrins or their substituted analogs, salts or hydrates are selected from the group consisting of sulfonated β-cyclodextrin, (2-hydroxypropyl)-β-cyclodextrin, methyl-β-cyclodextrin, acetyl-β-cyclodextrin, (2-hydroxyethyl)-β-cyclodextrin, triacetyl-β-cyclodextrin, heptath (2,3,6-tri-O-methyl)-β-cyclodextrin, succinyl-β-cyclodextrin, heptath (2,3,6-tri-O-benzoyl)-β-cyclodextrin, carboxymethyl-β-cyclodextrin, β-cyclodextrin hydrate, γ-cyclodextrin hydrate, (2-hydroxypropyl)-γ-cyclodextrin, and salts and combinations thereof. In one embodiment, the one or more water-soluble cyclodextrins include or are selected from sulfonated β-cyclodextrin or its salt (such as sodium or potassium salt). In some other embodiments, the one or more water-soluble macrocycles include or are selected from water-soluble calixarene or its optionally substituted analogs, salts or hydrates. In some further embodiments, the water-soluble calixarene or its optionally substituted analogs, salts or hydrates are selected from the group consisting of: 4-sulfonic calix[4]arene, 4-sulfonic calix[6]arene hydrate and 4-sulfothiacx[4]arene sodium salt, and combinations thereof. In some other embodiments, the one or more water-soluble macrocycles include or are selected from water-soluble cucurbituril or its optionally substituted analogs, salts or hydrates. In some further embodiments, the water-soluble cucurbituril or its optionally substituted analogs, salts or hydrates are selected from the group consisting of: cucurbit[5]uril hydrate, cucurbit[6]uril hydrate, cucurbit[7]uril hydrate and cucurbit[8]uril hydrate, and combinations thereof.In some such embodiments, the substituted analogs of the water-soluble calixarene or cucurbituril may be independently substituted with one or more substituents selected from the group consisting of sulfonate, sulfonate, hydroxyl, carboxyl, succinyl, C1-C6 alkyl, C1-C6 alkyl substituted with sulfonate, sulfonate, carboxyl, carboxylate or hydroxyl, (C1-C6 alkyl)-C(=O)-, or a hydroxyl protecting group (such as -C(=O)CH3 (acetyl) and -C(=O)Ph (benzoyl), or a combination thereof). In some embodiments, the molar ratio of the water-soluble macrocycle (or its analog, salt or hydrate) to the Pd catalyst is about 20:1 to 1:20, about 10:1 to about 1:10, or about 5:1 to about 1:5. For example, the molar ratio of the water-soluble macrocycle (or its analog, salt or hydrate) to the Pd catalyst is about 1: 1, 2: 1, 3: 1, 4: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1 or 10: 1. In one embodiment, the molar ratio of the water-soluble cyclodextrin (or its analog, salt or hydrate) to the Pd catalyst is about 4: 1. In some embodiments, the pH of the aqueous cleavage mixture is about 7.0 to about 10 or about 7.5 to about 9.5.

[0232] In some embodiments of the kits described herein, the aqueous cleavage solution further comprises one or more oxygen scavengers and / or phosphine reducing agents as described herein. In some embodiments, the one or more additives in the aqueous cleavage solution prevent or reduce the formation of palladium clusters (e.g., when the Pd cleavage solution is under thermal stress). In some embodiments, the one or more additives in the aqueous cleavage solution prevent or reduce oxidation and / or thermal degradation of the active Pd catalyst (e.g., active Pd(0) species).

[0233] Some embodiments of the kit further include a spike-in mixture, wherein the spike-in mixture comprises one or more types of nucleotides from four different types of nucleotides (e.g., four different types of nucleotides from A, T, C, and G or U; dATP, dTTP, dCTP, and dGTP or dUTP), wherein each of the nucleotides has a 3' blocking group as described herein and at least one Pd(0) scavenger as described herein. In other embodiments, the 3' blocking group contains an unsubstituted or substituted allyl group, for example, the 3' blocking group has a structure attached to the 3' oxygen of the nucleotide. Where R a , R b , R c , R d and R e Each of is independently H, halogen, unsubstituted or substituted C1-C6 alkyl or C1-C6 haloalkyl. In another embodiment, the 3' blocking group of the nucleotide has a structure connected to the 3' oxygen of the nucleotide In some additional embodiments, the Pd(0) scavenger comprises one or more allyl moieties selected from the group consisting of: -O-allyl, -S-allyl, -NR-allyl, and -N-allyl. + RR'-allyl, and combinations thereof, wherein R is H, unsubstituted or substituted C1-C6 alkyl, unsubstituted or substituted C2-C6 alkenyl, unsubstituted or substituted C2-C6 alkynyl, unsubstituted or substituted C6-C 10 aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, unsubstituted or substituted C3-C 10 carbocyclyl, or unsubstituted or substituted 5 to 10 membered heterocyclyl; and R′ is H, unsubstituted C1-C6 alkyl or substituted C1-C6 alkyl. In another embodiment, the Pd(0) scavenger comprising one or more –O-allyl moieties is or a salt thereof. In another embodiment, the compound comprises one or more -NR-allyl or -N + The RR'-allyl moiety of the Pd(0) scavenger is Where Z - It is Cl - or F - In another embodiment, the incorporation mixture is in lyophilized form.

[0234] Some embodiments of the kit further include an aqueous wash solution or a composition capable of being reconstituted into an aqueous wash solution. In some embodiments, the aqueous wash solution comprises at least one Pd(II) scavenger described herein.

[0235] The present disclosure also provides a box for use with a sequencing device, the box comprising a plurality of chambers, wherein one or more of the plurality of chambers are used for use with a kit comprising an aqueous lysis mixture as described herein or a kit as described herein. For example, the box may comprise two or more separate chambers, one chamber comprising an aqueous lysis mixture as described herein, and another chamber comprising an incorporation mixture as described herein.

[0236] Example

[0237] Additional embodiments are disclosed in more detail in the following examples, which are not intended to limit the scope of the claims in any way.

[0238] Example 1. Effects of oxidation and thermal stress on Pd pyrolysis mixture

[0239] In this example, two independent mechanisms by which the active Pd(0) complex can decompose (thus reducing cleavage activity) are demonstrated based on solution kinetic data. Figure 1AIn the experiment, a standard Pd cleavage mixture (also called universal cleavage mixture or UCM) was subjected to oxygen stress for 5 hours, and the cleavage percentage of the 3' capping group was compared with that of fresh UCM. It was observed that oxygen stress significantly reduced the cleavage activity of UCM.

[0240] In addition, UCM can also undergo thermal decomposition. Thermal decomposition leads to the formation of Pd clusters, and the final precipitation of Pd clusters reduces the amount of active material available for cleavage. Figure 1B In Figure 3, dynamic light scattering (DLS) data showed the formation of Pd cluster nanoparticles after 7 days of thermal stress at 55 °C compared to fresh UCM.

[0241] Example 2. Efficiency of Cyclodextrin Additives on Oxygen and Thermally Stressed Pd Cleavage Mixtures

[0242] In this example, various cyclodextrin analogs were tested in a plate reader assay. In the plate reader assay, a non-fluorescent allylic analog of fluorescein was cleaved by a Pd cleavage mixture and the released fluorescence was measured by a plate reader. The fluorescence is proportional to the amount of Pd(0) present in the sample. The residual percentage of Pd(0) active material relative to a fresh sample is plotted. As a control, a standard Pd cleavage mixture (UCM) was used to determine the residual active Pd(0) before and after 5 hours of oxygen stress. Compared to the standard UCM, acetyl-β-cyclodextrin showed promising stability improvements and an increase in residual Pd(0) after oxygen stress ( Figure 2 ).

[0243] In addition, various cyclodextrin analogs were tested in a solution kinetic assay with a standard Pd cleavage mixture (UCM) before and after 5 hours of oxygen stress to determine the residual cleavage percentage of the 3' capping group. Both acetyl-β-cyclodextrin and sulfonate-β-cyclodextrin showed promising stability improvements and increases in residual cleavage percentage after oxygen stress compared to the standard UCM ( Figure 3A ). In addition, acetyl-β-cyclodextrin and sulfonate-β-cyclodextrin also increased the stability of UCM under thermal stress by preventing the formation of Pd nanoparticle clusters in the cleavage mixture when segmented at 55 °C, as shown by DLS ( Figure 3B ).exist Figure 3B In Figure 3, DLS results show that the addition of cyclodextrin prevents the formation of aggregates after 7 days of heat stress at 55°C compared to UCM.

[0244] All of the above data show the potential of cyclodextrins to achieve longer ambient storage and longer instrument stability.

[0245] Example 3. Effect of oxygen scavengers and phosphine reducing agents on the stability of Pd pyrolysis mixtures

[0246] In this example, the effects of additives, including oxygen scavengers and phosphine reducing agents, were tested in a solution kinetic assay to evaluate the effectiveness of these additives in preventing or reducing oxidation of a Pd cleavage mixture (UCM), as measured by the percent cleavage of 3'-capped nucleotides. In this example, the percent cleavage was measured after 1 minute and after 60 minutes. Oxygen scavengers including sulfite-based oxygen scavengers, such as sodium sulfite, sodium bisulfite, and sodium metabisulfite, were tested. Initial analytical studies showed that UCM containing sodium sulfite, sodium bisulfite, and sodium metabisulfite had more Pd(0) active species after oxidative stress compared to control UCM samples. In addition, the solution kinetic assay showed better residual percent cleavage activity (%Pd(0)) for sodium bisulfite. Figure 4 ). Sequencing analysis of oxidatively stressed UCM samples containing sulfite showed that the UCM containing the additive had comparable sequencing measurements compared to the control UCM. The phosphine reducing agent sildenafil was tested with different ratios of THP:sildenafil. The analytical data showed promising data for UCM containing 1:3 and 1:5 THP:sildenafil. Sequencing data for the stressed samples showed reduced activity compared to the control UCM.

Claims

1. A method for sequencing a plurality of different target polynucleotides, the method comprising: (a) contacting a solid support with a spike-in mixture comprising a DNA polymerase and one or more types of nucleotides among four different types of nucleotides and a sequencing primer that is complementary to and hybridizes to at least a portion of the target polynucleotide, wherein the solid support comprises a plurality of different target polynucleotides immobilized thereon; (b) incorporating one type of nucleotide into the sequencing primer to generate an extended copy polynucleotide, wherein each of the four types of nucleotides comprises a 3' blocking group; (c) imaging the extended copy polynucleotide and performing one or more fluorescence measurements; and (d) removing the 3' blocking group of the incorporated nucleotide in an aqueous cleavage solution comprising an active palladium catalyst; wherein the aqueous cleavage solution comprises one or more additives for improving the thermal or oxidative stability of the active palladium catalyst, and wherein the one or more additives comprise one or more water-soluble macrocycles.

2. The process according to claim 1, wherein the active palladium catalyst is Pd(0).

3. The method of claim 2, wherein the Pd(0) is formed in situ from a Pd(II) complex and one or more water-soluble phosphines.

4. The method according to claim 3, wherein the Pd(II) complex comprises [Pd(allyl)Cl]2, Na2PdCl4, K2PdCl4, Li2PdCl4, [Pd(allyl)(THP)]Cl, [Pd(allyl)(THP)2]Cl, Pd(CH3CN)2Cl2, Pd(OAc)2, Pd(PPh3)4, Pd(dba)2, Pd(Acac)2, PdCl2(COD), Pd(TFA)2, Na2PdBr4, K2PdBr4, PdCl2, PdBr2 or Pd(NO3)2, or a combination thereof.

5. The method of claim 4, wherein the Pd(II) complex comprises [Pd(allyl)Cl]2 or Na2PdCl4.

6. The method of any one of claims 3 to 5, wherein the one or more water-soluble phosphines comprises tris(hydroxypropyl)phosphine (THP), tris(hydroxymethyl)phosphine (THMP), 1,3,5-triaza-7-phosphaadamantane (PTA), bis(p-sulfonatophenyl)phenylphosphine dihydrate potassium salt, tris(carboxyethyl)phosphine (TCEP) or triphenylphosphine-3,3',3"-trisulfonic acid trisodium salt, or a combination thereof.

7. The method of claim 6, wherein the one or more water-soluble phosphines comprises THP.

8. The method according to any one of claims 1 to 7, wherein the one or more water-soluble macrocycles comprises a water-soluble cyclodextrin or an optionally substituted analog, salt or hydrate thereof.

9. The method of claim 8, wherein the water-soluble cyclodextrin or the analog, salt or hydrate thereof comprises β-cyclodextrin, γ-cyclodextrin or a substituted analog or salt thereof, or a combination thereof.

10. The method of claim 8, wherein the substituted analogs of the water-soluble cyclodextrin are independently substituted with one or more substituents selected from the group consisting of sulfonate, sulfo, hydroxy, carboxyl, succinyl, C1-C6 alkyl, C1-C6 alkyl substituted with sulfo, sulfonate, carboxyl, carboxylate or hydroxy, (C1-C6 alkyl)-C(=O)-, -C(=O)CH3, -C(=O)Ph and hydroxyl protecting groups, and combinations thereof.

11. The method of any one of claims 1 to 10, wherein the one or more water-soluble cyclodextrins or substituted analogs, salts or hydrates thereof are selected from the group consisting of sulfonated β-cyclodextrin, (2-hydroxypropyl)-β-cyclodextrin, methyl-β-cyclodextrin, acetyl-β-cyclodextrin, (2-hydroxyethyl)-β-cyclodextrin, triacetyl-β-cyclodextrin, heptath(2,3,6-tri-O-methyl)-β-cyclodextrin, succinyl-β-cyclodextrin, heptath(2,3,6-tri-O-benzoyl)-β-cyclodextrin, carboxymethyl-β-cyclodextrin, β-cyclodextrin hydrate, γ-cyclodextrin hydrate, (2-hydroxypropyl)-γ-cyclodextrin, and salts and combinations thereof.

12. The method of claim 11, wherein the one or more water-soluble cyclodextrins comprise sulfonated β-cyclodextrin or a salt thereof.

13. The method of any one of claims 1 to 7, wherein the one or more water-soluble macrocycles comprises a water-soluble calixarene or an optionally substituted analog, salt or hydrate thereof.

14. The method of claim 13, wherein the water-soluble calixarene or an optionally substituted analog, salt or hydrate thereof is selected from the group consisting of 4-sulfonicalix[4]arene, 4-sulfonicalix[6]arene hydrate and 4-sulfothiacix[4]arene sodium salt, and combinations thereof.

15. The method of any one of claims 1 to 7, wherein the one or more water-soluble macrocycles comprises a water-soluble cucurbituril or an optionally substituted analog, salt or hydrate thereof.

16. The method of claim 15, wherein the water-soluble cucurbituril or its optionally substituted analog, salt or hydrate is selected from the group consisting of cucurbit[5]uril hydrate, cucurbit[6]uril hydrate, cucurbit[7]uril hydrate and cucurbit[8]uril hydrate, and combinations thereof.

17. The method according to any one of claims 1 to 16, wherein the aqueous cleavage solution further comprises one or more oxygen scavengers and / or phosphine reducing agents.

18. The method of claim 17, wherein the one or more oxygen scavengers comprise sodium sulfite, sodium bisulfite, or sodium metabisulfite, or a combination thereof.

19. The method of claim 17, wherein the one or more phosphine reducing agents comprise borohydride, borane, or silane, or a combination thereof.

20. The method of any one of claims 1 to 19, wherein the one or more additives in the aqueous cleavage solution prevent or reduce the formation of palladium clusters.

21. The method of any one of claims 1 to 20, wherein the one or more additives in the aqueous cleavage solution prevent or reduce oxidation and / or thermal degradation of the active Pd catalyst.

22. The method of any one of claims 1 to 21, further comprising (e) washing the solid support with an aqueous washing solution.

23. The method of claim 22, wherein steps (a) to (e) are repeated at least 50, 100, 150, 200, 250 or 300 cycles to determine the target polynucleotide sequence.

24. The process of claim 22 or 23, wherein the aqueous wash solution comprises at least one Pd(II) scavenger.

25. The process according to any one of claims 22 to 24, wherein the dosing mixture and / or the aqueous washing solution further comprises at least one Pd(0) scavenger.

26. The method according to any one of claims 1 to 25, wherein the one or more types of nucleotides of the four different types of nucleotides include A, C, G and T or U, and at least one type of nucleotide further carries a detectable label.

27. The method of claim 26, wherein the aqueous lysis solution also removes the detectable label.

28. A method for improving the stability of a composition comprising an active palladium catalyst, the method comprising: An aqueous composition comprising a Pd(0) catalyst is mixed with one or more additives for improving the thermal or oxidative stability of the active palladium catalyst, wherein the one or more additives comprise one or more water-soluble macrocycles.

29. The method of claim 28, wherein the Pd(0) is formed in situ from a Pd(II) complex and one or more water-soluble phosphines.

30. The method of claim 29, wherein the Pd(II) complex comprises [Pd(allyl)Cl]2, Na2PdCl4, K2PdCl4, Li2PdCl4, [Pd(allyl)(THP)]Cl, [Pd(allyl)(THP)2]Cl, Pd(CH3CN)2Cl2, Pd(OAc)2, Pd(PPh3)4, Pd(dba)2, Pd(Acac)2, PdCl2(COD), Pd(TFA)2, Na2PdBr4, K2PdBr4, PdCl2, PdBr2 or Pd(NO3)2, or a combination thereof.

31. The method of claim 29 or 30, wherein the one or more water-soluble phosphines comprises tri(hydroxypropyl)phosphine (THP), tri(hydroxymethyl)phosphine (THMP), 1,3,5-triaza-7-phosphaadamantane (PTA), bis(p-sulfonatophenyl)phenylphosphine dihydrate potassium salt, tri(carboxyethyl)phosphine (TCEP) or triphenylphosphine-3,3',3"-trisulfonic acid trisodium salt, or a combination thereof.

32. The method of any one of claims 28 to 31, wherein the one or more water-soluble macrocycles comprises a water-soluble cyclodextrin or an optionally substituted analog, salt or hydrate thereof.

33. The method of claim 32, wherein the water-soluble cyclodextrin or the optionally substituted analog, salt or hydrate thereof comprises β-cyclodextrin, γ-cyclodextrin or a substituted analog or salt thereof, or a combination thereof.

34. The method of claim 33, wherein the substituted analogs of the water-soluble cyclodextrin are independently substituted with one or more substituents selected from the group consisting of sulfonate, sulfo, hydroxy, carboxyl, succinyl, C1-C6 alkyl, C1-C6 alkyl substituted with sulfo, sulfonate, carboxyl, carboxylate or hydroxy, (C1-C6 alkyl)-C(=O)-, -C(=O)CH3, -C(=O)Ph and hydroxyl protecting groups, and combinations thereof.

35. The method of any one of claims 28 to 34, wherein the one or more water-soluble cyclodextrins or the substituted analogs, salts or hydrates thereof are selected from the group consisting of sulfonated β-cyclodextrin, (2-hydroxypropyl)-β-cyclodextrin, methyl-β-cyclodextrin, acetyl-β-cyclodextrin, (2-hydroxyethyl)-β-cyclodextrin, triacetyl-β-cyclodextrin, heptath(2,3,6-tri-O-methyl)-β-cyclodextrin, succinyl-β-cyclodextrin, heptath(2,3,6-tri-O-benzoyl)-β-cyclodextrin, carboxymethyl-β-cyclodextrin, β-cyclodextrin hydrate, γ-cyclodextrin hydrate, (2-hydroxypropyl)-γ-cyclodextrin, and salts and combinations thereof.

36. The method of any one of claims 28 to 31, wherein the one or more water-soluble macrocycles comprises a water-soluble calixarene or an optionally substituted analog, salt or hydrate thereof.

37. The method of claim 36, wherein the water-soluble calixarene or an optionally substituted analog, salt or hydrate thereof is selected from the group consisting of 4-sulfonicalix[4]arene, 4-sulfonicalix[6]arene hydrate and 4-sulfothiacalix[4]arene sodium salt, and combinations thereof.

38. The method of any one of claims 28 to 31, wherein the one or more water-soluble macrocycles comprises a water-soluble cucurbituril or an optionally substituted analog, salt or hydrate thereof.

39. The method of claim 38, wherein the water-soluble cucurbituril or its optionally substituted analog, salt or hydrate is selected from the group consisting of cucurbit[5]uril hydrate, cucurbit[6]uril hydrate, cucurbit[7]uril hydrate and cucurbit[8]uril hydrate, and combinations thereof.

40. The method of any one of claims 28 to 39, wherein the aqueous composition further comprises one or more oxygen scavengers and / or phosphine reducing agents.

41. The method of claim 40, wherein the one or more oxygen scavengers comprises sodium sulfite, sodium bisulfite, or sodium metabisulfite, or a combination thereof.

42. The method of claim 40, wherein the one or more phosphine reducing agents comprise borohydride, borane, or silane, or a combination thereof.

43. The method of any one of claims 28 to 42, wherein the one or more additives in the containing composition prevent or reduce the formation of palladium clusters.

44. The method of any one of claims 28 to 43, wherein the one or more additives in the aqueous composition prevent or reduce oxidation and / or thermal degradation of the active Pd(0) catalyst.

45. A kit for use with a sequencing device, the kit comprising: an aqueous cleavage mixture comprising an active Pd(0) catalyst; and One or more additives for improving the thermal or oxidative stability of the active Pd(0) catalyst, and wherein the one or more additives comprise one or more water-soluble macrocycles.

46. ​​The kit of claim 45, wherein the Pd(0) is formed in situ from a Pd(II) complex and one or more water-soluble phosphines.

47. The kit of claim 46, wherein the Pd(II) complex comprises [Pd(allyl)Cl]2, Na2PdCl4, K2PdCl4, Li2PdCl4, [Pd(allyl)(THP)]Cl, [Pd(allyl)(THP)2]Cl, Pd(CH3CN)2Cl2, Pd(OAc)2, Pd(PPh3)4, Pd(dba)2, Pd(Acac)2, PdCl2(COD), Pd(TFA)2, Na2PdBr4, K2PdBr4, PdCl2, PdBr2 or Pd(NO3)2, or a combination thereof.

48. The kit of claim 47, wherein the Pd(II) complex comprises [Pd(allyl)Cl]2 or Na2PdCl4.

49. The kit according to any one of claims 46 to 48, wherein the one or more water-soluble phosphines include tris(hydroxypropyl)phosphine (THP), tris(hydroxymethyl)phosphine (THMP), 1,3,5-triaza-7-phosphaadamantane (PTA), bis(p-sulfonatophenyl)phenylphosphine dihydrate potassium salt, tri(carboxyethyl)phosphine (TCEP) or triphenylphosphine-3,3',3"-trisulfonic acid trisodium salt, or a combination thereof.

50. The kit of claim 49, wherein the one or more water-soluble phosphines comprises THP.

51. The kit of any one of claims 42 to 50, wherein the water-soluble macrocycle comprises a water-soluble cyclodextrin or an optionally substituted analog, salt or hydrate thereof.

52. The kit of claim 51, wherein the water-soluble cyclodextrin or the optionally substituted analog, salt or hydrate thereof comprises β-cyclodextrin, γ-cyclodextrin or a substituted analog or salt thereof, or a combination thereof.

53. A kit according to claim 51, wherein the substituted analogs of the water-soluble cyclodextrin are independently substituted with one or more substituents, and the one or more substituents are selected from the group consisting of: sulfonate, sulfo, hydroxyl, carboxyl, succinyl, C1-C6 alkyl, C1-C6 alkyl substituted with sulfo, sulfonate, carboxyl, carboxylate or hydroxyl, (C1-C6 alkyl)-C(=O)-, -C(=O)CH3, -C(=O)Ph and hydroxyl protecting groups, and combinations thereof.

54. A kit according to any one of claims 45 to 53, wherein the one or more water-soluble cyclodextrins or the substituted analogs, salts or hydrates thereof are selected from the group consisting of sulfonated β-cyclodextrin, (2-hydroxypropyl)-β-cyclodextrin, methyl-β-cyclodextrin, acetyl-β-cyclodextrin, (2-hydroxyethyl)-β-cyclodextrin, triacetyl-β-cyclodextrin, heptath(2,3,6-tri-O-methyl)-β-cyclodextrin, succinyl-β-cyclodextrin, heptath(2,3,6-tri-O-benzoyl)-β-cyclodextrin, carboxymethyl-β-cyclodextrin, β-cyclodextrin hydrate, γ-cyclodextrin hydrate, (2-hydroxypropyl)-γ-cyclodextrin, and salts and combinations thereof.

55. The kit of claim 54, wherein the one or more water-soluble cyclodextrins comprise sulfonated β-cyclodextrin or a salt thereof.

56. A kit according to any one of claims 45 to 55, wherein the aqueous lysis solution further comprises one or more oxygen scavengers and / or phosphine reducing agents.

57. The kit of claim 56, wherein the one or more oxygen scavengers and / or phosphine reducing agents comprise sodium sulfite, sodium bisulfite, sodium metabisulfite, silane, borohydride, borane, or combinations thereof.

58. The kit of any one of claims 45 to 57, further comprising a spike-in mixture, wherein the spike-in mixture comprises a DNA polymerase and one or more of four different types of nucleotides, each type of nucleotide having a 3' blocking group.

59. The kit of claim 58, wherein the 3' capping group comprises an optionally substituted allyl group.

60. The kit of claim 59, wherein the 3' blocking group has a structure linked to the 3' oxygen of the nucleotide 61. The kit of any one of claims 58 to 60, wherein the dosing mixture further comprises at least one Pd(0) scavenger.

62. A kit according to any one of claims 42 to 61 further comprising an aqueous washing solution or a composition capable of being reconstituted into an aqueous washing solution.

63. The kit of claim 62, wherein the aqueous wash solution comprises at least one Pd(II) scavenger.

64. A box for use with a sequencing device, the box comprising a plurality of chambers, wherein one or more chambers of the plurality of chambers are used with the kit according to any one of claims 45 to 63.